[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGbvW6sBtJ5_68DFvU-e3tZNPHHxEGHi4ot4FMukHsPk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Daewoong Pharmaceutical Co. LTD.",[4],197,false,27,50,184416,41,13,[14,17,19,22,25,28,31,33],{"name":15,"count":16},"Healthy",53,{"name":18,"count":12},"Healthy Volunteers",{"name":20,"count":21},"Hypertension",9,{"name":23,"count":24},"T2DM (Type 2 Diabetes Mellitus)",8,{"name":26,"count":27},"Dyslipidemias",6,{"name":29,"count":30},"Diabetes Mellitus, Type 2",5,{"name":32,"count":30},"Dyslipidemia",{"name":34,"count":35},"Idiopathic Pulmonary Fibrosis",4,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05614765","Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment","2023-12-31","Statin+Ezetimibe compound",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05660135","Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","2024-11-30","Olmesartan Medoxomil\u002F Amlodipine Besylate\u002F Rosuvastatin Ca",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06644404","Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults","2024-12-03","DWP16001 0.3mg",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05889143","A Study to Evaluate the Efficacy and Safety of CREZET Tablet","2024-12-31","Ezetimibe\u002FRosuvastatin",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06592495","Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315","2025-01","Period 1",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05926414","To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus","2025-01-17","Enavogliflozin",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05411887","Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab","2025-03-31","Rosuvastatin, Olmesartan Medoxomil",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07144176","PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers","2025-09","DWJ1511",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06647888","Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia","2025-12-31","Envlo",{"nctId":83,"briefTitle":84,"date":80,"intervention":85},"NCT07013279","Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","DWP712 inj.",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,155,181,199,217,262,456,482,500,523,541,590,638,660,684,702,720,738,764,782,800,818,839,857,886,904,922,953,971,989,1007,1025,1043,1061,1091,1111,1131,1149,1169,1187,1208,1227,1265,1290,1315,1340,1364,1389,1407,1432,1458,1476,1494,1519,1545,1563,1589,1607,1631,1649,1672,1716,1746,1788,1820,1874,1912,1941,1978,2016,2049,2071,2108,2144,2177,2209,2231,2253,2275,2309,2334,2352,2378,2396,2419,2444,2462,2485,2503,2521,2539,2564,2591,2609,2627,2645,2670,2697,2715,2733,2751,2776,2794,2819,2837,2864,2882,2900,2918,2936,2954,2972,2990,3018,3036,3054,3072,3090,3117,3135,3153,3171,3189,3207,3225,3243,3261,3279,3297,3321,3345,3363,3381,3431,3471,3507,3525,3550,3568,3586,3604,3656,3686,3730,3761,3789,3811,3847,3877,3909,3931,3961,3983,4017,4052,4084,4106,4124,4142,4160,4178,4205,4223,4241,4259,4277,4299,4324,4342,4360,4386,4404,4422,4447,4465,4483,4501,4519,4537,4563,4581,4599,4617,4635,4659,4677,4701,4719,4737,4761,4779,4804,4822,4840,4863,4881,4904,4922,4940,4964,4982,5000,5018,5042,5060,5083,5106,5124,5142,5160,5178,5196,5223,5241,5259,5284,5302,5325,5343,5361,5384,5407,5425,5449,5475,5493,5511,5534,5552,5577,5595,5613,5638,5656,5682,5700,5718,5739,5762,5785,5803,5825,5843,5866,5884,5902,5920,5938,5962,5980,5998,6016,6034,6052,6070,6095,6113,6131,6153,6171,6189,6207,6225,6243,6261,6342,6370,6403,6435,6460,6478,6496,6519,6542],{"intervention":95,"totalTrials":96,"cells":97},"Lansoprazole 15 mg placebo",3,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":137,"NA":153},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[107,122],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT04784910","Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer","COMPLETED",[90],"2023-11-27","2023-12-11","2021-05-21",423,[117],"Peptic Ulcer",[119,120,121,95],"DWP14012 20mg","Lansoprazole 15 mg","DWP14012 20mg placebo",{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT04341428","Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis","UNKNOWN",[90],"2021-08-30","2021-12-30","2020-07-02",406,[132],"Healed Erosive Esophagitis",[134,135,120,136],"DWP14012 20 mg","DWP14012 20 mg placebo","Lansoprazole 15 mg Placebo",{"trials":138,"activeCount":152,"soonestReadout":144},[139],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT07533266","Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer","NOT_YET_RECRUITING",[91],"2027-12","2026-04",360,[148],"NSAID (Non-Steroidal Anti-Inflammatory Drug)",[150,95,120,151],"Fexuprazan 20mg","Fexuprazan 20mg placebo",1,{"trials":154,"activeCount":100},[],{"intervention":120,"totalTrials":96,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":173,"NA":179},{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":100},[],{"trials":162,"activeCount":100},[],{"trials":164,"activeCount":100},[165,169],{"nctId":108,"briefTitle":109,"status":110,"phases":166,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":167,"interventions":168},[90],[117],[119,120,121,95],{"nctId":123,"briefTitle":124,"status":125,"phases":170,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":171,"interventions":172},[90],[132],[134,135,120,136],{"trials":174,"activeCount":152,"soonestReadout":144},[175],{"nctId":140,"briefTitle":141,"status":142,"phases":176,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":177,"interventions":178},[91],[148],[150,95,120,151],{"trials":180,"activeCount":100},[],{"intervention":150,"totalTrials":152,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":197},{"trials":184,"activeCount":100},[],{"trials":186,"activeCount":100},[],{"trials":188,"activeCount":100},[],{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":152,"soonestReadout":144},[193],{"nctId":140,"briefTitle":141,"status":142,"phases":194,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":195,"interventions":196},[91],[148],[150,95,120,151],{"trials":198,"activeCount":100},[],{"intervention":151,"totalTrials":152,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":100},[],{"trials":206,"activeCount":100},[],{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":152,"soonestReadout":144},[211],{"nctId":140,"briefTitle":141,"status":142,"phases":212,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":213,"interventions":214},[91],[148],[150,95,120,151],{"trials":216,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":232,"PHASE3":234,"PHASE4":258,"NA":260},{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":152,"soonestReadout":50},[223],{"nctId":48,"briefTitle":49,"status":142,"phases":224,"primaryCompletion":50,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},[88],"2025-04-01","2024-10-26",34,[15],[51,230,231],"DWC202407 1,000mg","DWC202408 2mg",{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":152,"soonestReadout":251},[236,247],{"nctId":237,"briefTitle":238,"status":125,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":245},"NCT05466643","A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus",[90],"2024-09-30","2023-03-17",240,[244],"Type 2 Diabetes Mellitus",[51,246],"DWP16001 Placebo",{"nctId":248,"briefTitle":249,"status":142,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT06606093","Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients",[90],"2026-09-01","2027-01-31","2024-09-23",348,[256],"Type 2 Diabetic Nephropathy",[246,51],{"trials":259,"activeCount":100},[],{"trials":261,"activeCount":100},[],{"intervention":263,"totalTrials":264,"cells":265},"DWP16001",17,{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":395,"PHASE3":407,"PHASE4":452,"NA":454},{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[270,283,293,304,314,324,335,346,356,364,375,384],{"nctId":271,"briefTitle":272,"status":125,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT05737771","To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination",[88],"2023-03-31","2023-06-30","2023-01-25",40,[279,29],"FDC",[281,282,263],"DWC202213","DWJ1563",{"nctId":284,"briefTitle":285,"status":125,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT05797922","To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers",[88],"2023-05-31","2023-11-30","2023-03-09",32,[15],[263],{"nctId":294,"briefTitle":295,"status":110,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT05192395","A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers",[88],"2022-05-24","2022-04-15",37,[15],[302,263,303],"DWJ1525","DWC202101",{"nctId":305,"briefTitle":306,"status":125,"phases":307,"primaryCompletion":308,"completion":308,"start":309,"enrollment":227,"conditions":310,"interventions":311},"NCT04343547","Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults",[88],"2020-07","2020-04",[15],[263,312,313],"DWC202001+DWC202002","DWP16001+DWC202001+DWC202002",{"nctId":315,"briefTitle":316,"status":125,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},"NCT05207176","Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities",[88],"2022-04-08","2022-08-31","2022-02-14",24,[15],[263],{"nctId":325,"briefTitle":326,"status":110,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT07213310","Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults",[88],"2026-01-07","2025-11-09",18,[15],[263,333,334],"DWC202511","DWC202512",{"nctId":336,"briefTitle":337,"status":110,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT03364985","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers",[88],"2019-05-21","2019-07-30","2017-12-03",123,[15],[263,345],"Dapagliflozin",{"nctId":347,"briefTitle":348,"status":110,"phases":349,"primaryCompletion":350,"completion":350,"start":351,"enrollment":227,"conditions":352,"interventions":353},"NCT04064073","Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)",[88],"2019-11-20","2019-08-14",[15],[263,354,355],"Metformin IR","DWP16001+Metformin IR",{"nctId":357,"briefTitle":358,"status":125,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":321,"conditions":362,"interventions":363},"NCT05747664","To Compare the Safety and PK\u002FPD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function",[88],"2024-04-30","2023-04-13",[29],[263],{"nctId":365,"briefTitle":366,"status":125,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":374},"NCT04221399","Type 2 Diabetes Patients With Renal Impairment",[88],"2020-08","2020-10","2020-01",35,[373],"Type2 Diabetes",[263,263],{"nctId":376,"briefTitle":377,"status":125,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":321,"conditions":381,"interventions":382},"NCT05321732","The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults",[88],"2022-08","2021-12-10",[18],[263,383],"DWP202010",{"nctId":385,"briefTitle":386,"status":125,"phases":387,"primaryCompletion":388,"completion":389,"start":390,"enrollment":16,"conditions":391,"interventions":392},"NCT05500898","Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults",[88],"2022-10-31","2023-02-28","2022-08-26",[15],[263,393,394],"DWC202204+DWC202205","DWP16001+DWC202204+DWC202205",{"trials":396,"activeCount":100},[397],{"nctId":398,"briefTitle":399,"status":125,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":406},"NCT04014023","Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus",[89],"2020-03","2020-06","2019-07-10",196,[23],[263],{"trials":408,"activeCount":152,"soonestReadout":413},[409,419,434,443],{"nctId":410,"briefTitle":411,"status":142,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":417},"NCT07619833","To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus",[90],"2027-11","2026-06",510,[23],[263,418],"DWC202518",{"nctId":420,"briefTitle":421,"status":125,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":432},"NCT05505994","The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin",[90],"2024-02-26","2024-09","2022-09-28",340,[428,29,429,430,431],"Diabetes Mellitus","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases",[263,345,246,433],"Dapagliflozin Placebo",{"nctId":435,"briefTitle":436,"status":110,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT04632862","The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.",[90],"2021-11-25","2020-11-11",140,[23],[263],{"nctId":444,"briefTitle":445,"status":110,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":451},"NCT05376969","Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin",[90],"2022-05-16","2021-05-25",159,[23],[263],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"intervention":246,"totalTrials":96,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":478,"NA":480},{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":100},[],{"trials":465,"activeCount":152,"soonestReadout":251},[466,470,474],{"nctId":237,"briefTitle":238,"status":125,"phases":467,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":468,"interventions":469},[90],[244],[51,246],{"nctId":420,"briefTitle":421,"status":125,"phases":471,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":472,"interventions":473},[90],[428,29,429,430,431],[263,345,246,433],{"nctId":248,"briefTitle":249,"status":142,"phases":475,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":476,"interventions":477},[90],[256],[246,51],{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"intervention":418,"totalTrials":152,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":496,"NA":498},{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":152,"soonestReadout":413},[492],{"nctId":410,"briefTitle":411,"status":142,"phases":493,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":494,"interventions":495},[90],[23],[263,418],{"trials":497,"activeCount":100},[],{"trials":499,"activeCount":100},[],{"intervention":85,"totalTrials":152,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":519,"NA":521},{"trials":503,"activeCount":100},[],{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":100},[],{"trials":509,"activeCount":152,"soonestReadout":80},[510],{"nctId":83,"briefTitle":84,"status":142,"phases":511,"primaryCompletion":80,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":517},[90],"2026-03-31","2025-07-15",324,[516],"Glabellar Lines",[85,518],"Botox® 100 Units",{"trials":520,"activeCount":100},[],{"trials":522,"activeCount":100},[],{"intervention":518,"totalTrials":152,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":531,"PHASE4":537,"NA":539},{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":100},[],{"trials":532,"activeCount":152,"soonestReadout":80},[533],{"nctId":83,"briefTitle":84,"status":142,"phases":534,"primaryCompletion":80,"completion":512,"start":513,"enrollment":514,"conditions":535,"interventions":536},[90],[516],[85,518],{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"intervention":542,"totalTrials":96,"cells":543},"DWN12088",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":571,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":100},[548,560],{"nctId":549,"briefTitle":550,"status":110,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":557},"NCT04888715","To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers",[88],"2021-08-02","2021-08-18","2021-07-23",48,[34],[542,558,559],"Pirfenidone","Nintedanib",{"nctId":561,"briefTitle":562,"status":110,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":321,"conditions":567,"interventions":568},"NCT04888728","To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers",[88],"2021-07-12","2021-07-27","2021-06-30",[34],[542,569,570],"Nebivolol","Paroxetine",{"trials":572,"activeCount":152,"soonestReadout":578},[573],{"nctId":574,"briefTitle":575,"status":576,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":583},"NCT05389215","Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF","RECRUITING",[89],"2026-10-13","2027-01-30","2022-07-29",102,[34],[542],{"trials":585,"activeCount":100},[],{"trials":587,"activeCount":100},[],{"trials":589,"activeCount":100},[],{"intervention":591,"totalTrials":96,"cells":592},"DWC202313, DWC202314",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":616,"PHASE3":618,"PHASE4":634,"NA":636},{"trials":594,"activeCount":100},[],{"trials":596,"activeCount":615,"soonestReadout":601},[597,608],{"nctId":598,"briefTitle":599,"status":576,"phases":600,"primaryCompletion":601,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":606},"NCT07267221","Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.",[88],"2026-01-30","2026-05-30","2025-12-01",36,[18],[607,591],"DWJ1622",{"nctId":609,"briefTitle":610,"status":576,"phases":611,"primaryCompletion":601,"completion":602,"start":612,"enrollment":277,"conditions":613,"interventions":614},"NCT07260851","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions",[88],"2025-11-05",[18],[607,591],2,{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[620],{"nctId":621,"briefTitle":622,"status":110,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT06671392","A Phase III Study to Efficacy and Safety of DWC202405\u002FDWC202313 and DWC202314 in Patients With Hypertension",[90],"2026-02-05","2025-02-24",198,[628],"Essential Hypertension",[630,631,632,591,633],"DWC202405","DWC202405, DWC202314","DWC202405, DWC202314P","DWC202313, DWC202314P",{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"intervention":607,"totalTrials":615,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":652,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":641,"activeCount":100},[],{"trials":643,"activeCount":615,"soonestReadout":601},[644,648],{"nctId":598,"briefTitle":599,"status":576,"phases":645,"primaryCompletion":601,"completion":602,"start":603,"enrollment":604,"conditions":646,"interventions":647},[88],[18],[607,591],{"nctId":609,"briefTitle":610,"status":576,"phases":649,"primaryCompletion":601,"completion":602,"start":612,"enrollment":277,"conditions":650,"interventions":651},[88],[18],[607,591],{"trials":653,"activeCount":100},[],{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"intervention":61,"totalTrials":152,"cells":661},{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":663,"activeCount":100},[],{"trials":665,"activeCount":152,"soonestReadout":60},[666],{"nctId":58,"briefTitle":59,"status":142,"phases":667,"primaryCompletion":60,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":672},[88],"2025-10","2024-10",52,[18],[61,673,674,675],"Period 2","Period 3","Period 4",{"trials":677,"activeCount":100},[],{"trials":679,"activeCount":100},[],{"trials":681,"activeCount":100},[],{"trials":683,"activeCount":100},[],{"intervention":673,"totalTrials":152,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":687,"activeCount":100},[],{"trials":689,"activeCount":152,"soonestReadout":60},[690],{"nctId":58,"briefTitle":59,"status":142,"phases":691,"primaryCompletion":60,"completion":668,"start":669,"enrollment":670,"conditions":692,"interventions":693},[88],[18],[61,673,674,675],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":100},[],{"trials":701,"activeCount":100},[],{"intervention":674,"totalTrials":152,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":705,"activeCount":100},[],{"trials":707,"activeCount":152,"soonestReadout":60},[708],{"nctId":58,"briefTitle":59,"status":142,"phases":709,"primaryCompletion":60,"completion":668,"start":669,"enrollment":670,"conditions":710,"interventions":711},[88],[18],[61,673,674,675],{"trials":713,"activeCount":100},[],{"trials":715,"activeCount":100},[],{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":100},[],{"intervention":675,"totalTrials":152,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":723,"activeCount":100},[],{"trials":725,"activeCount":152,"soonestReadout":60},[726],{"nctId":58,"briefTitle":59,"status":142,"phases":727,"primaryCompletion":60,"completion":668,"start":669,"enrollment":670,"conditions":728,"interventions":729},[88],[18],[61,673,674,675],{"trials":731,"activeCount":100},[],{"trials":733,"activeCount":100},[],{"trials":735,"activeCount":100},[],{"trials":737,"activeCount":100},[],{"intervention":739,"totalTrials":152,"cells":740},"DWZ2501",{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":756,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":152,"soonestReadout":749},[745],{"nctId":746,"briefTitle":747,"status":576,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":277,"conditions":751,"interventions":754},"NCT07371104","Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer",[88],"2027-03","2026-04-22",[752,753],"Cancer","Ovarian Cancer",[739,755],"DWC202510",{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"trials":761,"activeCount":100},[],{"trials":763,"activeCount":100},[],{"intervention":755,"totalTrials":152,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":152,"soonestReadout":749},[770],{"nctId":746,"briefTitle":747,"status":576,"phases":771,"primaryCompletion":749,"completion":749,"start":750,"enrollment":277,"conditions":772,"interventions":773},[88],[752,753],[739,755],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"trials":779,"activeCount":100},[],{"trials":781,"activeCount":100},[],{"intervention":230,"totalTrials":152,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":785,"activeCount":100},[],{"trials":787,"activeCount":152,"soonestReadout":50},[788],{"nctId":48,"briefTitle":49,"status":142,"phases":789,"primaryCompletion":50,"completion":225,"start":226,"enrollment":227,"conditions":790,"interventions":791},[88],[15],[51,230,231],{"trials":793,"activeCount":100},[],{"trials":795,"activeCount":100},[],{"trials":797,"activeCount":100},[],{"trials":799,"activeCount":100},[],{"intervention":231,"totalTrials":152,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":152,"soonestReadout":50},[806],{"nctId":48,"briefTitle":49,"status":142,"phases":807,"primaryCompletion":50,"completion":225,"start":226,"enrollment":227,"conditions":808,"interventions":809},[88],[15],[51,230,231],{"trials":811,"activeCount":100},[],{"trials":813,"activeCount":100},[],{"trials":815,"activeCount":100},[],{"trials":817,"activeCount":100},[],{"intervention":76,"totalTrials":152,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":152,"soonestReadout":75},[824],{"nctId":73,"briefTitle":74,"status":576,"phases":825,"primaryCompletion":75,"completion":75,"start":75,"enrollment":826,"conditions":827,"interventions":829},[88],60,[828],"Healthy Subjects",[76,830],"DWC202501",{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":100},[],{"trials":838,"activeCount":100},[],{"intervention":830,"totalTrials":152,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":152,"soonestReadout":75},[845],{"nctId":73,"briefTitle":74,"status":576,"phases":846,"primaryCompletion":75,"completion":75,"start":75,"enrollment":826,"conditions":847,"interventions":848},[88],[828],[76,830],{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[],{"intervention":858,"totalTrials":152,"cells":859},"DWRX5003",{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":152,"soonestReadout":868},[864],{"nctId":865,"briefTitle":866,"status":142,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":875},"NCT07539415","A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers",[88],"2026-04-30","2026-08-30","2026-03-30",72,[873,874],"Obesity & Overweight","Type 2 Diabetes",[858,876,877],"DWC202502","DWC202503",{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":100},[],{"intervention":876,"totalTrials":152,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":902},{"trials":889,"activeCount":100},[],{"trials":891,"activeCount":152,"soonestReadout":868},[892],{"nctId":865,"briefTitle":866,"status":142,"phases":893,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":894,"interventions":895},[88],[873,874],[858,876,877],{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":100},[],{"trials":903,"activeCount":100},[],{"intervention":877,"totalTrials":152,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":152,"soonestReadout":868},[910],{"nctId":865,"briefTitle":866,"status":142,"phases":911,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":912,"interventions":913},[88],[873,874],[858,876,877],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[],{"intervention":923,"totalTrials":152,"cells":924},"DWP212525 10mg",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":951},{"trials":926,"activeCount":100},[],{"trials":928,"activeCount":152,"soonestReadout":933},[929],{"nctId":930,"briefTitle":931,"status":576,"phases":932,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":936,"interventions":938},"NCT06736587","A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers",[88],"2026-06-30","2024-12-10",76,[937],"Autoimmune Diseases",[923,939,940,941,942,943,944],"DWP212525 30mg","DWP212525 50mg","DWP212525 100mg","DWP212525 200mg","DWP212525 400mg","DWP212525 placebo",{"trials":946,"activeCount":100},[],{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":100},[],{"trials":952,"activeCount":100},[],{"intervention":939,"totalTrials":152,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":152,"soonestReadout":933},[959],{"nctId":930,"briefTitle":931,"status":576,"phases":960,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":961,"interventions":962},[88],[937],[923,939,940,941,942,943,944],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[],{"trials":970,"activeCount":100},[],{"intervention":940,"totalTrials":152,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":974,"activeCount":100},[],{"trials":976,"activeCount":152,"soonestReadout":933},[977],{"nctId":930,"briefTitle":931,"status":576,"phases":978,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":979,"interventions":980},[88],[937],[923,939,940,941,942,943,944],{"trials":982,"activeCount":100},[],{"trials":984,"activeCount":100},[],{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":100},[],{"intervention":941,"totalTrials":152,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":152,"soonestReadout":933},[995],{"nctId":930,"briefTitle":931,"status":576,"phases":996,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":997,"interventions":998},[88],[937],[923,939,940,941,942,943,944],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":100},[],{"intervention":942,"totalTrials":152,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":152,"soonestReadout":933},[1013],{"nctId":930,"briefTitle":931,"status":576,"phases":1014,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":1015,"interventions":1016},[88],[937],[923,939,940,941,942,943,944],{"trials":1018,"activeCount":100},[],{"trials":1020,"activeCount":100},[],{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"intervention":943,"totalTrials":152,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":152,"soonestReadout":933},[1031],{"nctId":930,"briefTitle":931,"status":576,"phases":1032,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":1033,"interventions":1034},[88],[937],[923,939,940,941,942,943,944],{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"intervention":944,"totalTrials":152,"cells":1044},{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":152,"soonestReadout":933},[1049],{"nctId":930,"briefTitle":931,"status":576,"phases":1050,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":1051,"interventions":1052},[88],[937],[923,939,940,941,942,943,944],{"trials":1054,"activeCount":100},[],{"trials":1056,"activeCount":100},[],{"trials":1058,"activeCount":100},[],{"trials":1060,"activeCount":100},[],{"intervention":81,"totalTrials":615,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1064,"activeCount":100},[],{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":615,"soonestReadout":80},[1075,1081],{"nctId":78,"briefTitle":79,"status":576,"phases":1076,"primaryCompletion":80,"completion":933,"start":50,"enrollment":1077,"conditions":1078,"interventions":1079},[],12000,[29],[81,1080],"Envlomet SR",{"nctId":1082,"briefTitle":1083,"status":1084,"phases":1085,"primaryCompletion":80,"completion":933,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT06427083","Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus","ACTIVE_NOT_RECRUITING",[],"2024-06-11",200,[244],[81,1090],"Envolomet SR",{"intervention":41,"totalTrials":152,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1094,"activeCount":100},[],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":152,"soonestReadout":40},[1105],{"nctId":38,"briefTitle":39,"status":1084,"phases":1106,"primaryCompletion":40,"completion":80,"start":1107,"enrollment":1108,"conditions":1109,"interventions":1110},[],"2022-07-08",18000,[26],[41],{"intervention":46,"totalTrials":152,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[],{"trials":1118,"activeCount":100},[],{"trials":1120,"activeCount":100},[],{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":152,"soonestReadout":45},[1125],{"nctId":43,"briefTitle":44,"status":1084,"phases":1126,"primaryCompletion":45,"completion":80,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1130},[],"2022-06-20",4000,[20,26],[46],{"intervention":1080,"totalTrials":152,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":152,"soonestReadout":80},[1145],{"nctId":78,"briefTitle":79,"status":576,"phases":1146,"primaryCompletion":80,"completion":933,"start":50,"enrollment":1077,"conditions":1147,"interventions":1148},[],[29],[81,1080],{"intervention":71,"totalTrials":152,"cells":1150},{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"trials":1162,"activeCount":152,"soonestReadout":70},[1163],{"nctId":68,"briefTitle":69,"status":1084,"phases":1164,"primaryCompletion":70,"completion":80,"start":1127,"enrollment":1165,"conditions":1166,"interventions":1168},[],2845,[1167,20],"Hyperlipidemias",[71],{"intervention":1090,"totalTrials":152,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":100},[],{"trials":1182,"activeCount":152,"soonestReadout":80},[1183],{"nctId":1082,"briefTitle":1083,"status":1084,"phases":1184,"primaryCompletion":80,"completion":933,"start":1086,"enrollment":1087,"conditions":1185,"interventions":1186},[],[244],[81,1090],{"intervention":56,"totalTrials":152,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":152,"soonestReadout":55},[1201],{"nctId":53,"briefTitle":54,"status":1084,"phases":1202,"primaryCompletion":55,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1207},[],"2026-03-01","2023-05-24",15000,[26],[56],{"intervention":66,"totalTrials":152,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":100},[],{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[],{"trials":1221,"activeCount":152,"soonestReadout":65},[1222],{"nctId":63,"briefTitle":64,"status":1084,"phases":1223,"primaryCompletion":65,"completion":80,"start":1224,"enrollment":1205,"conditions":1225,"interventions":1226},[],"2023-09-21",[29],[66,66],{"intervention":1228,"totalTrials":615,"cells":1229},"DWJ1464",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1247,"PHASE3":1249,"PHASE4":1251,"NA":1263},{"trials":1231,"activeCount":100},[],{"trials":1233,"activeCount":100},[1234],{"nctId":1235,"briefTitle":1236,"status":125,"phases":1237,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1243},"NCT04477369","Safety and Pharmacokinetics of DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Volunteers",[88],"2020-08-31","2020-09","2020-08-06",28,[15],[1244,1228,1245,1246],"DWJ1439","DWC202003","DWC202004",{"trials":1248,"activeCount":100},[],{"trials":1250,"activeCount":100},[],{"trials":1252,"activeCount":100},[1253],{"nctId":1254,"briefTitle":1255,"status":110,"phases":1256,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},"NCT06272630","Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease",[91],"2024-03-29","2023-02-06",263,[1261],"Chronic Liver Disease",[1228],{"trials":1264,"activeCount":100},[],{"intervention":1266,"totalTrials":152,"cells":1267},"Ursodeoxycholic acid, thiamine, riboflavin",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1288},{"trials":1269,"activeCount":100},[],{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[1278],{"nctId":1279,"briefTitle":1280,"status":110,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1287},"NCT02415777","Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction",[91],"2015-07","2014-10",168,[1286],"Fatigue",[1266],{"trials":1289,"activeCount":100},[],{"intervention":1291,"totalTrials":152,"cells":1292},"Patients who continued UDCA 300mg medication",{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1301,"NA":1313},{"trials":1294,"activeCount":100},[],{"trials":1296,"activeCount":100},[],{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[],{"trials":1302,"activeCount":100},[1303],{"nctId":1304,"briefTitle":1305,"status":110,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1312},"NCT05410535","To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy",[91],"2022-10-28","2021-09-15",431,[1311],"Gastric Cancer",[1291],{"trials":1314,"activeCount":100},[],{"intervention":1316,"totalTrials":152,"cells":1317},"Luphere depot 3.75mg",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1338},{"trials":1319,"activeCount":100},[],{"trials":1321,"activeCount":100},[],{"trials":1323,"activeCount":100},[],{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[1328],{"nctId":1329,"briefTitle":1330,"status":110,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1337},"NCT01634321","The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty",[91],"2012-08","2011-07",63,[1336],"Central Precocious Puberty",[1316],{"trials":1339,"activeCount":100},[],{"intervention":1341,"totalTrials":152,"cells":1342},"Choline alfoscerate",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1362},{"trials":1344,"activeCount":100},[],{"trials":1346,"activeCount":100},[],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[1353],{"nctId":1354,"briefTitle":1355,"status":125,"phases":1356,"primaryCompletion":1357,"start":1282,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT02648906","A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients",[91],"2018-11",128,[1360],"Alzheimer Disease",[1341],{"trials":1363,"activeCount":100},[],{"intervention":1365,"totalTrials":152,"cells":1366},"Tiropramide HCl 100mg",{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1387},{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[1377],{"nctId":1378,"briefTitle":1379,"status":125,"phases":1380,"primaryCompletion":1381,"completion":1381,"start":1382,"conditions":1383,"interventions":1385},"NCT01629212","Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome",[91],"2013-02","2011-12",[1384],"Irritable Bowel Syndrome",[1365,1386],"Octylonium bromide 20mg",{"trials":1388,"activeCount":100},[],{"intervention":1386,"totalTrials":152,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1405},{"trials":1392,"activeCount":100},[],{"trials":1394,"activeCount":100},[],{"trials":1396,"activeCount":100},[],{"trials":1398,"activeCount":100},[],{"trials":1400,"activeCount":100},[1401],{"nctId":1378,"briefTitle":1379,"status":125,"phases":1402,"primaryCompletion":1381,"completion":1381,"start":1382,"conditions":1403,"interventions":1404},[91],[1384],[1365,1386],{"trials":1406,"activeCount":100},[],{"intervention":1408,"totalTrials":152,"cells":1409},"Single group, open-label",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1430},{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"trials":1415,"activeCount":100},[],{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":100},[1420],{"nctId":1421,"briefTitle":1422,"status":110,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1429},"NCT02568150","Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines",[91],"2014-03","2014-02",45,[1428],"Moderate-severe Glabellar Lines",[1408],{"trials":1431,"activeCount":100},[],{"intervention":1433,"totalTrials":152,"cells":1434},"OLOMAX 20\u002F5\u002F5mg",{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1443,"NA":1456},{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[1445],{"nctId":1446,"briefTitle":1447,"status":110,"phases":1448,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1451,"conditions":1452,"interventions":1453},"NCT04120753","Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab",[91],"2021-07-06","2019-08-26",106,[20,26],[1433,1454,1455],"OLOMAX 20\u002F5\u002F10mg","Olmesartan 20 mg\u002FAmlodipine 5 mg",{"trials":1457,"activeCount":100},[],{"intervention":1454,"totalTrials":152,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1474},{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[],{"trials":1465,"activeCount":100},[],{"trials":1467,"activeCount":100},[],{"trials":1469,"activeCount":100},[1470],{"nctId":1446,"briefTitle":1447,"status":110,"phases":1471,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1451,"conditions":1472,"interventions":1473},[91],[20,26],[1433,1454,1455],{"trials":1475,"activeCount":100},[],{"intervention":1455,"totalTrials":152,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1484,"PHASE4":1486,"NA":1492},{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[1488],{"nctId":1446,"briefTitle":1447,"status":110,"phases":1489,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1451,"conditions":1490,"interventions":1491},[91],[20,26],[1433,1454,1455],{"trials":1493,"activeCount":100},[],{"intervention":1495,"totalTrials":152,"cells":1496},"Albis Tab",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1517},{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[1507],{"nctId":1508,"briefTitle":1509,"status":125,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1333,"enrollment":1513,"conditions":1514,"interventions":1516},"NCT01397240","The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients",[91],"2012-01","2013-06",80,[1515],"Patients Taking Low-dose Aspirin",[1495],{"trials":1518,"activeCount":100},[],{"intervention":1520,"totalTrials":152,"cells":1521},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1543},{"trials":1523,"activeCount":100},[],{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[1532],{"nctId":1533,"briefTitle":1534,"status":110,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1541},"NCT03485534","Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients",[91],"2019-11-04","2018-01-23",189,[1540],"Hepatitis B, Chronic",[1520,1542],"Tenofovir Disoproxil",{"trials":1544,"activeCount":100},[],{"intervention":1542,"totalTrials":152,"cells":1546},{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1561},{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[],{"trials":1552,"activeCount":100},[],{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":100},[1557],{"nctId":1533,"briefTitle":1534,"status":110,"phases":1558,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":1538,"conditions":1559,"interventions":1560},[91],[1540],[1520,1542],{"trials":1562,"activeCount":100},[],{"intervention":1564,"totalTrials":152,"cells":1565},"Mucotra SR Tablet 150mg",{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1587},{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[1576],{"nctId":1577,"briefTitle":1578,"status":110,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1585},"NCT05072938","Clinical Trial to Compare Rebamipide\u002FNizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis",[91],"2022-12-15","2021-09-30",260,[1584],"Gastritis",[1564,1586],"Axid Capsule 150mg",{"trials":1588,"activeCount":100},[],{"intervention":1586,"totalTrials":152,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1605},{"trials":1592,"activeCount":100},[],{"trials":1594,"activeCount":100},[],{"trials":1596,"activeCount":100},[],{"trials":1598,"activeCount":100},[],{"trials":1600,"activeCount":100},[1601],{"nctId":1577,"briefTitle":1578,"status":110,"phases":1602,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1603,"interventions":1604},[91],[1584],[1564,1586],{"trials":1606,"activeCount":100},[],{"intervention":1608,"totalTrials":152,"cells":1609},"Vemliver",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1629},{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":100},[1620],{"nctId":1621,"briefTitle":1622,"status":110,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":404,"conditions":1626,"interventions":1627},"NCT06000657","Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir",[91],"2025-02-03","2023-08-28",[1540],[1608,1628],"Baracross",{"trials":1630,"activeCount":100},[],{"intervention":1628,"totalTrials":152,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1639,"PHASE4":1641,"NA":1647},{"trials":1634,"activeCount":100},[],{"trials":1636,"activeCount":100},[],{"trials":1638,"activeCount":100},[],{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[1643],{"nctId":1621,"briefTitle":1622,"status":110,"phases":1644,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":404,"conditions":1645,"interventions":1646},[91],[1540],[1608,1628],{"trials":1648,"activeCount":100},[],{"intervention":1650,"totalTrials":152,"cells":1651},"Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1660,"NA":1670},{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":100},[],{"trials":1657,"activeCount":100},[],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[1662],{"nctId":1663,"briefTitle":1664,"status":110,"phases":1665,"primaryCompletion":1666,"completion":1666,"start":1283,"enrollment":1667,"conditions":1668,"interventions":1669},"NCT02418130","A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.",[91],"2015-03",166,[1286],[1650],{"trials":1671,"activeCount":100},[],{"intervention":1673,"totalTrials":96,"cells":1674},"DWJ1252",{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1689,"PHASE3":1691,"PHASE4":1712,"NA":1714},{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[1679],{"nctId":1680,"briefTitle":1681,"status":110,"phases":1682,"primaryCompletion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1688},"NCT01094847","Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine",[88],"2010-05","2010-04",30,[1687],"Bioequivalence",[1673],{"trials":1690,"activeCount":100},[],{"trials":1692,"activeCount":100},[1693,1704],{"nctId":1694,"briefTitle":1695,"status":110,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT03184402","Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)",[90],"2017-07-31","2017-04-24",124,[1701],"Functional Dyspepsia",[1673,1703],"Gasmotin",{"nctId":1705,"briefTitle":1706,"status":110,"phases":1707,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":1699,"conditions":1710,"interventions":1711},"NCT03024086","Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia",[90],"2017-04-25","2016-12-12",[1701],[1673,1703],{"trials":1713,"activeCount":100},[],{"trials":1715,"activeCount":100},[],{"intervention":345,"totalTrials":96,"cells":1717},{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1726,"PHASE3":1728,"PHASE4":1742,"NA":1744},{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[1722],{"nctId":336,"briefTitle":337,"status":110,"phases":1723,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":1724,"interventions":1725},[88],[15],[263,345],{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":100},[1730,1738],{"nctId":1731,"briefTitle":1732,"status":110,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":1087,"conditions":1736,"interventions":1737},"NCT04634500","The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.",[90],"2021-11-03","2020-11-18",[23],[345],{"nctId":420,"briefTitle":421,"status":125,"phases":1739,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":1740,"interventions":1741},[90],[428,29,429,430,431],[263,345,246,433],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"intervention":1747,"totalTrials":96,"cells":1748},"DWJ211",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1761,"PHASE3":1773,"PHASE4":1784,"NA":1786},{"trials":1750,"activeCount":100},[],{"trials":1752,"activeCount":100},[1753],{"nctId":1754,"briefTitle":1755,"status":110,"phases":1756,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":330,"conditions":1759,"interventions":1760},"NCT04159961","Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers",[88],"2020-04-21","2019-12-24",[15],[1747],{"trials":1762,"activeCount":100},[1763],{"nctId":1764,"briefTitle":1765,"status":110,"phases":1766,"primaryCompletion":1767,"completion":1767,"start":1768,"enrollment":440,"conditions":1769,"interventions":1771},"NCT03224117","Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat",[89],"2018-06-29","2017-10-26",[1770],"Treatment for Submental Fat",[1747,1772],"Normal saline",{"trials":1774,"activeCount":100},[1775],{"nctId":1776,"briefTitle":1777,"status":110,"phases":1778,"primaryCompletion":129,"completion":129,"start":1779,"enrollment":1780,"conditions":1781,"interventions":1783},"NCT03946592","Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat",[90],"2019-05-15",148,[1782],"Submental Fat",[1772,1747],{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"intervention":1772,"totalTrials":96,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1804,"PHASE3":1810,"PHASE4":1816,"NA":1818},{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":100},[1794],{"nctId":1795,"briefTitle":1796,"status":125,"phases":1797,"primaryCompletion":566,"completion":1798,"start":1799,"enrollment":604,"conditions":1800,"interventions":1801},"NCT04827472","Study to Evaluate the Safety\u002FTolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers",[88],"2021-07-31","2021-01-20",[15],[1772,1802,1803],"DWJ1521","DWP14012",{"trials":1805,"activeCount":100},[1806],{"nctId":1764,"briefTitle":1765,"status":110,"phases":1807,"primaryCompletion":1767,"completion":1767,"start":1768,"enrollment":440,"conditions":1808,"interventions":1809},[89],[1770],[1747,1772],{"trials":1811,"activeCount":100},[1812],{"nctId":1776,"briefTitle":1777,"status":110,"phases":1813,"primaryCompletion":129,"completion":129,"start":1779,"enrollment":1780,"conditions":1814,"interventions":1815},[90],[1782],[1772,1747],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"intervention":1821,"totalTrials":96,"cells":1822},"DWP14012 40mg",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1870,"NA":1872},{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[1831,1843,1859],{"nctId":1832,"briefTitle":1833,"status":110,"phases":1834,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1259,"conditions":1837,"interventions":1839},"NCT03736369","Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)",[90],"2019-08-07","2018-12-13",[1838],"Erosive Esophagitis",[1821,1840,1841,1842],"DWP14012 40mg placebo","Esomeprazole 40mg","Esomeprazole 40mg placebo",{"nctId":1844,"briefTitle":1845,"status":110,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1854},"NCT06751121","Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori",[90],"2025-04-24","2024-02-06",461,[1851,1852,1853],"Helicobacter Pylori Infection","Helicobacter Pylori Infected Patients","Helicobacter Pylori Infected Subjects",[1821,1855,1856,1857,1858,1840],"DWC202301 30mg","Amoxicillin 1000mg","Clarithromycin 500mg","DWC202301 30mg placebo",{"nctId":1860,"briefTitle":1861,"status":125,"phases":1862,"primaryCompletion":60,"completion":1863,"start":1864,"enrollment":514,"conditions":1865,"interventions":1869},"NCT06121830","Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)",[90],"2025-03","2023-08-31",[1866,1867,1868],"Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease","Non-Erosive Esophageal Reflux Disease",[119,1821],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"intervention":1875,"totalTrials":615,"cells":1876},"DWP450",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1908,"NA":1910},{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[],{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[1885,1897],{"nctId":1886,"briefTitle":1887,"status":110,"phases":1888,"primaryCompletion":1889,"completion":1890,"start":1891,"enrollment":1892,"conditions":1893,"interventions":1895},"NCT06354127","DWP450 for Treating Moderate to Severe Glabellar Lines",[90],"2020-11-24","2021-01-25","2020-08-12",473,[1894],"Moderate to Severe Glabellar Lines",[1875,1896],"Botox®",{"nctId":1898,"briefTitle":1899,"status":110,"phases":1900,"primaryCompletion":1901,"completion":1902,"start":1903,"enrollment":1904,"conditions":1905,"interventions":1907},"NCT04294251","Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy",[90],"2021-01-07","2021-08-10","2020-03-04",180,[1906],"Benign Masseteric Hypertrophy",[1875],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"intervention":1896,"totalTrials":615,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1929,"PHASE3":1931,"PHASE4":1937,"NA":1939},{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[1918],{"nctId":1919,"briefTitle":1920,"status":110,"phases":1921,"primaryCompletion":423,"completion":1922,"start":1923,"enrollment":1924,"conditions":1925,"interventions":1926},"NCT06212960","Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines",[88],"2024-03-21","2023-11-28",20,[516],[1927,1928],"DWP712","BOTOX®",{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[1933],{"nctId":1886,"briefTitle":1887,"status":110,"phases":1934,"primaryCompletion":1889,"completion":1890,"start":1891,"enrollment":1892,"conditions":1935,"interventions":1936},[90],[1894],[1875,1896],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"intervention":1942,"totalTrials":615,"cells":1943},"DWJ1248",{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1958,"PHASE3":1960,"PHASE4":1974,"NA":1976},{"trials":1945,"activeCount":100},[],{"trials":1947,"activeCount":100},[1948],{"nctId":1949,"briefTitle":1950,"status":110,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1957},"NCT04782505","Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers",[88],"2021-03-16","2021-06-28","2021-03-12",61,[15],[1942],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[1962],{"nctId":1963,"briefTitle":1964,"status":1965,"phases":1966,"primaryCompletion":1967,"completion":1968,"start":1969,"enrollment":21,"conditions":1970,"interventions":1973},"NCT04721535","A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2","TERMINATED",[90],"2021-09-23","2021-10-06","2021-06-07",[1971,1972],"Covid19","SARS-COV-2 Infection",[1942],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"intervention":1979,"totalTrials":615,"cells":1980},"DWJ1276",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1996,"PHASE3":1998,"PHASE4":2012,"NA":2014},{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[1985],{"nctId":1986,"briefTitle":1987,"status":110,"phases":1988,"primaryCompletion":1989,"completion":1990,"start":1511,"enrollment":1991,"conditions":1992,"interventions":1993},"NCT01493856","A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276",[88],"2012-02","2012-03",58,[18],[1994,1995,1979],"Cresto","Olmetec",{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[2000],{"nctId":2001,"briefTitle":2002,"status":110,"phases":2003,"primaryCompletion":2004,"completion":2005,"start":2006,"enrollment":2007,"conditions":2008,"interventions":2009},"NCT01764295","Clinical Study for Patients With Hypertension Associated With Dyslipidemia",[90],"2013-05","2013-07","2012-09",150,[20,32],[1979,2010,2011],"Olmesartan","Rosuvastatin",{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"intervention":2017,"totalTrials":615,"cells":2018},"DWC20155",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2032,"PHASE3":2034,"PHASE4":2045,"NA":2047},{"trials":2020,"activeCount":100},[],{"trials":2022,"activeCount":100},[2023],{"nctId":2024,"briefTitle":2025,"status":110,"phases":2026,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":277,"conditions":2029,"interventions":2030},"NCT02704559","Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects",[88],"2016-02","2015-12",[15],[2017,2031],"DWC20156",{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[2036],{"nctId":2037,"briefTitle":2038,"status":1965,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":2042,"conditions":2043,"interventions":2044},"NCT03184415","Efficacy and Safety of DWC20155\u002FDWC20156 Combination Therapy in Patients With Gastritis",[90],"2018-05-17","2017-07-03",230,[1584],[2017,2031],{"trials":2046,"activeCount":100},[],{"trials":2048,"activeCount":100},[],{"intervention":2031,"totalTrials":615,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2059,"PHASE3":2061,"PHASE4":2067,"NA":2069},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[2055],{"nctId":2024,"briefTitle":2025,"status":110,"phases":2056,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":277,"conditions":2057,"interventions":2058},[88],[15],[2017,2031],{"trials":2060,"activeCount":100},[],{"trials":2062,"activeCount":100},[2063],{"nctId":2037,"briefTitle":2038,"status":1965,"phases":2064,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":2042,"conditions":2065,"interventions":2066},[90],[1584],[2017,2031],{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"intervention":2072,"totalTrials":615,"cells":2073},"Amlodipine\u002FOlmesartan 10\u002F40mg",{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2104,"NA":2106},{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":100},[2082,2093],{"nctId":2083,"briefTitle":2084,"status":110,"phases":2085,"primaryCompletion":2086,"completion":2086,"start":2087,"enrollment":2088,"conditions":2089,"interventions":2090},"NCT03009487","A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan\u002FAmlodipine\u002FRosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia",[90],"2018-04","2017-01",265,[20,1167],[2091,2092,2072],"Amlodipine\u002FOlmesartan 10\u002F40mg (Combination drug), Rosuvastatin 20mg","Olmesartan 40 mg, Rosuvastatin 20mg",{"nctId":2094,"briefTitle":2095,"status":125,"phases":2096,"primaryCompletion":2097,"completion":2098,"start":350,"enrollment":2099,"conditions":2100,"interventions":2102},"NCT04161001","Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451",[90],"2021-11-20","2022-02-02",237,[2101],"Hypertension, Dyslipidemia",[2072,2103,2072],"Olmesartan 40mg, Ezetimibe\u002FRosuvastatin 10\u002F20mg",{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"intervention":2109,"totalTrials":615,"cells":2110},"Botulinum toxin type A",{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2115,"PHASE3":2127,"PHASE4":2140,"NA":2142},{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":100},[2117],{"nctId":2118,"briefTitle":2119,"status":125,"phases":2120,"primaryCompletion":2121,"completion":2121,"start":2122,"enrollment":2123,"conditions":2124,"interventions":2125},"NCT03369990","DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy",[89],"2018-10","2017-12",98,[1906],[2109,2126],"Placebos",{"trials":2128,"activeCount":100},[2129],{"nctId":2130,"briefTitle":2131,"status":110,"phases":2132,"primaryCompletion":2133,"completion":2134,"start":2135,"enrollment":6,"conditions":2136,"interventions":2139},"NCT01945684","A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity",[90],"2014-05","2014-07","2013-09",[2137,2138],"Spasticity","Stroke",[2109],{"trials":2141,"activeCount":100},[],{"trials":2143,"activeCount":100},[],{"intervention":2145,"totalTrials":615,"cells":2146},"rhEGF",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2153,"PHASE4":2173,"NA":2175},{"trials":2148,"activeCount":100},[],{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[],{"trials":2154,"activeCount":100},[2155,2164],{"nctId":2156,"briefTitle":2157,"status":125,"phases":2158,"primaryCompletion":2028,"completion":2028,"start":2159,"enrollment":2160,"conditions":2161,"interventions":2163},"NCT01099891","The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients",[90],"2010-03",300,[2162],"Stomatitis",[2145],{"nctId":2165,"briefTitle":2166,"status":110,"phases":2167,"primaryCompletion":2006,"completion":2006,"start":2168,"enrollment":2169,"conditions":2170,"interventions":2172},"NCT01629199","Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus",[90],"2010-10",176,[2171],"Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus",[2145],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[],{"intervention":2178,"totalTrials":615,"cells":2179},"DWP16001 Amg",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2205,"NA":2207},{"trials":2181,"activeCount":100},[],{"trials":2183,"activeCount":100},[],{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[2188,2196],{"nctId":2189,"briefTitle":2190,"status":110,"phases":2191,"primaryCompletion":2192,"completion":2192,"start":2193,"enrollment":1334,"conditions":2194,"interventions":2195},"NCT05376930","Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.",[90],"2022-05-31","2021-09-16",[23],[2178],{"nctId":2197,"briefTitle":2198,"status":110,"phases":2199,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2204},"NCT04654390","The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus",[90],"2021-12-17","2020-12-30",270,[23],[2178],{"trials":2206,"activeCount":100},[],{"trials":2208,"activeCount":100},[],{"intervention":1840,"totalTrials":615,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2217,"PHASE4":2227,"NA":2229},{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[2219,2223],{"nctId":1832,"briefTitle":1833,"status":110,"phases":2220,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1259,"conditions":2221,"interventions":2222},[90],[1838],[1821,1840,1841,1842],{"nctId":1844,"briefTitle":1845,"status":110,"phases":2224,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2225,"interventions":2226},[90],[1851,1852,1853],[1821,1855,1856,1857,1858,1840],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"intervention":119,"totalTrials":615,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2239,"PHASE4":2249,"NA":2251},{"trials":2234,"activeCount":100},[],{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[2241,2245],{"nctId":108,"briefTitle":109,"status":110,"phases":2242,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":2243,"interventions":2244},[90],[117],[119,120,121,95],{"nctId":1860,"briefTitle":1861,"status":125,"phases":2246,"primaryCompletion":60,"completion":1863,"start":1864,"enrollment":514,"conditions":2247,"interventions":2248},[90],[1866,1867,1868],[119,1821],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"intervention":1703,"totalTrials":615,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2271,"NA":2273},{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":100},[],{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[2263,2267],{"nctId":1694,"briefTitle":1695,"status":110,"phases":2264,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":2265,"interventions":2266},[90],[1701],[1673,1703],{"nctId":1705,"briefTitle":1706,"status":110,"phases":2268,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":1699,"conditions":2269,"interventions":2270},[90],[1701],[1673,1703],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"intervention":2276,"totalTrials":615,"cells":2277},"Clostridium Botulinum A Toxin",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2284,"PHASE4":2305,"NA":2307},{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[2286,2295],{"nctId":2287,"briefTitle":2288,"status":125,"phases":2289,"primaryCompletion":2290,"completion":2122,"start":2291,"enrollment":581,"conditions":2292,"interventions":2294},"NCT03184363","Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)",[90],"2017-10","2017-07",[2293,516],"Crow's Feet Lines",[2276],{"nctId":2296,"briefTitle":2297,"status":125,"phases":2298,"primaryCompletion":2087,"completion":2299,"start":2300,"enrollment":2301,"conditions":2302,"interventions":2304},"NCT02882893","Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines",[89,90],"2017-04","2016-08",238,[2303],"Crows Feet Lines",[2276,2276],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"intervention":2310,"totalTrials":152,"cells":2311},"somatropin",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2330,"NA":2332},{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[],{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[2320],{"nctId":2321,"briefTitle":2322,"status":110,"phases":2323,"primaryCompletion":2324,"completion":2324,"start":2325,"enrollment":670,"conditions":2326,"interventions":2328},"NCT02693522","Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency",[90],"2004-12","2003-10",[2327],"Growth Hormone Deficiency",[2310,2329],"Eutropin",{"trials":2331,"activeCount":100},[],{"trials":2333,"activeCount":100},[],{"intervention":2329,"totalTrials":152,"cells":2335},{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2348,"NA":2350},{"trials":2337,"activeCount":100},[],{"trials":2339,"activeCount":100},[],{"trials":2341,"activeCount":100},[],{"trials":2343,"activeCount":100},[2344],{"nctId":2321,"briefTitle":2322,"status":110,"phases":2345,"primaryCompletion":2324,"completion":2324,"start":2325,"enrollment":670,"conditions":2346,"interventions":2347},[90],[2327],[2310,2329],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"intervention":2353,"totalTrials":152,"cells":2354},"DWP14012 A mg",{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2374,"NA":2376},{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[2363],{"nctId":2364,"briefTitle":2365,"status":125,"phases":2366,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":2369,"conditions":2370,"interventions":2372},"NCT03811080","Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease",[90],"2020-02","2019-02-07",327,[2371],"Non-Erosive Gastroesophageal Reflux Disease",[2353,2373],"DWP14012 B mg",{"trials":2375,"activeCount":100},[],{"trials":2377,"activeCount":100},[],{"intervention":2373,"totalTrials":152,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":100},[],{"trials":2383,"activeCount":100},[],{"trials":2385,"activeCount":100},[],{"trials":2387,"activeCount":100},[2388],{"nctId":2364,"briefTitle":2365,"status":125,"phases":2389,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":2369,"conditions":2390,"interventions":2391},[90],[2371],[2353,2373],{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"intervention":2397,"totalTrials":152,"cells":2398},"DWP16001 0.3 mg",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2405,"PHASE4":2415,"NA":2417},{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[2407],{"nctId":2408,"briefTitle":2409,"status":125,"phases":2410,"primaryCompletion":75,"completion":75,"start":2411,"enrollment":2412,"conditions":2413,"interventions":2414},"NCT06141980","Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus",[90],"2023-12",134,[23],[2397],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[],{"intervention":2420,"totalTrials":152,"cells":2421},"Generic equivalent of Clostridium Botulinum A Toxin",{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2440,"NA":2442},{"trials":2423,"activeCount":100},[],{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"trials":2429,"activeCount":100},[2430],{"nctId":2431,"briefTitle":2432,"status":110,"phases":2433,"primaryCompletion":1332,"completion":2434,"start":1990,"enrollment":2435,"conditions":2436,"interventions":2438},"NCT01629875","Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line",[90],"2012-11",268,[2437],"Moderate to Severe Glabellar Line",[2420,2439],"Botox",{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"intervention":2439,"totalTrials":152,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2458,"NA":2460},{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[2454],{"nctId":2431,"briefTitle":2432,"status":110,"phases":2455,"primaryCompletion":1332,"completion":2434,"start":1990,"enrollment":2435,"conditions":2456,"interventions":2457},[90],[2437],[2420,2439],{"trials":2459,"activeCount":100},[],{"trials":2461,"activeCount":100},[],{"intervention":2463,"totalTrials":152,"cells":2464},"aclidinium bromide 400 μg",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2481,"NA":2483},{"trials":2466,"activeCount":100},[],{"trials":2468,"activeCount":100},[],{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[2473],{"nctId":2474,"briefTitle":2475,"status":110,"phases":2476,"primaryCompletion":2004,"completion":2004,"start":1332,"conditions":2477,"interventions":2479},"NCT01636401","Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[90],[2478],"COPD",[2463,2480],"aclidinium bromide placebo",{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"intervention":2480,"totalTrials":152,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2499,"NA":2501},{"trials":2488,"activeCount":100},[],{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":100},[],{"trials":2494,"activeCount":100},[2495],{"nctId":2474,"briefTitle":2475,"status":110,"phases":2496,"primaryCompletion":2004,"completion":2004,"start":1332,"conditions":2497,"interventions":2498},[90],[2478],[2463,2480],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"intervention":2091,"totalTrials":152,"cells":2504},{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2509,"PHASE3":2511,"PHASE4":2517,"NA":2519},{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[2513],{"nctId":2083,"briefTitle":2084,"status":110,"phases":2514,"primaryCompletion":2086,"completion":2086,"start":2087,"enrollment":2088,"conditions":2515,"interventions":2516},[90],[20,1167],[2091,2092,2072],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[],{"intervention":2092,"totalTrials":152,"cells":2522},{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2529,"PHASE4":2535,"NA":2537},{"trials":2524,"activeCount":100},[],{"trials":2526,"activeCount":100},[],{"trials":2528,"activeCount":100},[],{"trials":2530,"activeCount":100},[2531],{"nctId":2083,"briefTitle":2084,"status":110,"phases":2532,"primaryCompletion":2086,"completion":2086,"start":2087,"enrollment":2088,"conditions":2533,"interventions":2534},[90],[20,1167],[2091,2092,2072],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"intervention":2540,"totalTrials":152,"cells":2541},"Leuprolide Acetate 11.25 MG\u002FML",{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2546,"PHASE3":2548,"PHASE4":2560,"NA":2562},{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[2550],{"nctId":2551,"briefTitle":2552,"status":125,"phases":2553,"primaryCompletion":2554,"completion":2555,"start":2556,"enrollment":2557,"conditions":2558,"interventions":2559},"NCT06025409","Evaluate the Efficacy and Safety of DWJ108J",[90],"2025-02-28","2025-08-31","2023-08-01",79,[1336],[2540],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"intervention":2565,"totalTrials":152,"cells":2566},"DWJ1506",{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2571,"PHASE3":2573,"PHASE4":2587,"NA":2589},{"trials":2568,"activeCount":100},[],{"trials":2570,"activeCount":100},[],{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[2575],{"nctId":2576,"briefTitle":2577,"status":125,"phases":2578,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT04772443","Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507",[90],"2022-12","2021-02",280,[26],[2565,2584,2585,2586],"DWJ1507","DWC202011","DWJ1177",{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[],{"intervention":2584,"totalTrials":152,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2605,"NA":2607},{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[2601],{"nctId":2576,"briefTitle":2577,"status":125,"phases":2602,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":2581,"conditions":2603,"interventions":2604},[90],[26],[2565,2584,2585,2586],{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[],{"intervention":2585,"totalTrials":152,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2615,"PHASE3":2617,"PHASE4":2623,"NA":2625},{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":100},[],{"trials":2616,"activeCount":100},[],{"trials":2618,"activeCount":100},[2619],{"nctId":2576,"briefTitle":2577,"status":125,"phases":2620,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":2581,"conditions":2621,"interventions":2622},[90],[26],[2565,2584,2585,2586],{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"intervention":2586,"totalTrials":152,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2641,"NA":2643},{"trials":2630,"activeCount":100},[],{"trials":2632,"activeCount":100},[],{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[2637],{"nctId":2576,"briefTitle":2577,"status":125,"phases":2638,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":2581,"conditions":2639,"interventions":2640},[90],[26],[2565,2584,2585,2586],{"trials":2642,"activeCount":100},[],{"trials":2644,"activeCount":100},[],{"intervention":2646,"totalTrials":152,"cells":2647},"DWJ1248 with Remdesivir",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2666,"NA":2668},{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[2656],{"nctId":2657,"briefTitle":2658,"status":1965,"phases":2659,"primaryCompletion":2660,"completion":2661,"start":2662,"enrollment":242,"conditions":2663,"interventions":2665},"NCT04713176","Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients",[90],"2022-05-02","2022-12-09","2021-02-02",[2664],"Severe COVID-19",[2646],{"trials":2667,"activeCount":100},[],{"trials":2669,"activeCount":100},[],{"intervention":2671,"totalTrials":152,"cells":2672},"(D) DWC202206",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2693,"NA":2695},{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[2681],{"nctId":2682,"briefTitle":2683,"status":110,"phases":2684,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":2687,"conditions":2688,"interventions":2689},"NCT05643508","A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia",[90],"2024-09-10","2023-02-23",214,[20,1167],[2671,2690,2691,2692],"(D) DWC202207","(P) DWC202206","(P) DWC202207",{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"intervention":2690,"totalTrials":152,"cells":2698},{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2705,"PHASE4":2711,"NA":2713},{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"trials":2704,"activeCount":100},[],{"trials":2706,"activeCount":100},[2707],{"nctId":2682,"briefTitle":2683,"status":110,"phases":2708,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":2687,"conditions":2709,"interventions":2710},[90],[20,1167],[2671,2690,2691,2692],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"intervention":2691,"totalTrials":152,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2723,"PHASE4":2729,"NA":2731},{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[],{"trials":2724,"activeCount":100},[2725],{"nctId":2682,"briefTitle":2683,"status":110,"phases":2726,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":2687,"conditions":2727,"interventions":2728},[90],[20,1167],[2671,2690,2691,2692],{"trials":2730,"activeCount":100},[],{"trials":2732,"activeCount":100},[],{"intervention":2692,"totalTrials":152,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"trials":2742,"activeCount":100},[2743],{"nctId":2682,"briefTitle":2683,"status":110,"phases":2744,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":2687,"conditions":2745,"interventions":2746},[90],[20,1167],[2671,2690,2691,2692],{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"intervention":2752,"totalTrials":152,"cells":2753},"DWC202404, DWC202314",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2772,"NA":2774},{"trials":2755,"activeCount":100},[],{"trials":2757,"activeCount":100},[],{"trials":2759,"activeCount":100},[],{"trials":2761,"activeCount":100},[2762],{"nctId":2763,"briefTitle":2764,"status":110,"phases":2765,"primaryCompletion":2766,"completion":2766,"start":2767,"enrollment":2768,"conditions":2769,"interventions":2770},"NCT06682000","Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension",[90],"2025-10-02","2025-01-20",192,[20,628],[2752,2771],"DWC202404, DWC202314P",{"trials":2773,"activeCount":100},[],{"trials":2775,"activeCount":100},[],{"intervention":2771,"totalTrials":152,"cells":2777},{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2790,"NA":2792},{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[],{"trials":2785,"activeCount":100},[2786],{"nctId":2763,"briefTitle":2764,"status":110,"phases":2787,"primaryCompletion":2766,"completion":2766,"start":2767,"enrollment":2768,"conditions":2788,"interventions":2789},[90],[20,628],[2752,2771],{"trials":2791,"activeCount":100},[],{"trials":2793,"activeCount":100},[],{"intervention":2795,"totalTrials":152,"cells":2796},"Novosis",{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2815,"NA":2817},{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[2805],{"nctId":2806,"briefTitle":2807,"status":110,"phases":2808,"primaryCompletion":2809,"completion":2809,"start":2810,"conditions":2811,"interventions":2813},"NCT01634308","Efficacy and Safety of Bongros-BMP Compared to Bio-oss for Regeneration of Alveolar Bone Tissue After Maxillary Sinus Floor Augmentation",[90],"2012-06","2010-06",[2812],"Regeneration of Alveolar Tissue After Maxillary Sinus Floor Augmentation",[2795,2814],"Bio-oss",{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":100},[],{"intervention":2814,"totalTrials":152,"cells":2820},{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2825,"PHASE3":2827,"PHASE4":2833,"NA":2835},{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":100},[],{"trials":2826,"activeCount":100},[],{"trials":2828,"activeCount":100},[2829],{"nctId":2806,"briefTitle":2807,"status":110,"phases":2830,"primaryCompletion":2809,"completion":2809,"start":2810,"conditions":2831,"interventions":2832},[90],[2812],[2795,2814],{"trials":2834,"activeCount":100},[],{"trials":2836,"activeCount":100},[],{"intervention":2838,"totalTrials":152,"cells":2839},"DWJ1609",{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2846,"PHASE4":2860,"NA":2862},{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[],{"trials":2847,"activeCount":100},[2848],{"nctId":2849,"briefTitle":2850,"status":110,"phases":2851,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2858},"NCT06062030","Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy;",[90],"2024-06-03","2024-06-28","2024-03-08",215,[2857],"Colonoscopy",[2838,2859],"DWC202304",{"trials":2861,"activeCount":100},[],{"trials":2863,"activeCount":100},[],{"intervention":2859,"totalTrials":152,"cells":2865},{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2878,"NA":2880},{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[2874],{"nctId":2849,"briefTitle":2850,"status":110,"phases":2875,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2876,"interventions":2877},[90],[2857],[2838,2859],{"trials":2879,"activeCount":100},[],{"trials":2881,"activeCount":100},[],{"intervention":1841,"totalTrials":152,"cells":2883},{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2888,"PHASE3":2890,"PHASE4":2896,"NA":2898},{"trials":2885,"activeCount":100},[],{"trials":2887,"activeCount":100},[],{"trials":2889,"activeCount":100},[],{"trials":2891,"activeCount":100},[2892],{"nctId":1832,"briefTitle":1833,"status":110,"phases":2893,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1259,"conditions":2894,"interventions":2895},[90],[1838],[1821,1840,1841,1842],{"trials":2897,"activeCount":100},[],{"trials":2899,"activeCount":100},[],{"intervention":1842,"totalTrials":152,"cells":2901},{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2914,"NA":2916},{"trials":2903,"activeCount":100},[],{"trials":2905,"activeCount":100},[],{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":100},[2910],{"nctId":1832,"briefTitle":1833,"status":110,"phases":2911,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1259,"conditions":2912,"interventions":2913},[90],[1838],[1821,1840,1841,1842],{"trials":2915,"activeCount":100},[],{"trials":2917,"activeCount":100},[],{"intervention":1855,"totalTrials":152,"cells":2919},{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2932,"NA":2934},{"trials":2921,"activeCount":100},[],{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[2928],{"nctId":1844,"briefTitle":1845,"status":110,"phases":2929,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2930,"interventions":2931},[90],[1851,1852,1853],[1821,1855,1856,1857,1858,1840],{"trials":2933,"activeCount":100},[],{"trials":2935,"activeCount":100},[],{"intervention":1856,"totalTrials":152,"cells":2937},{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2950,"NA":2952},{"trials":2939,"activeCount":100},[],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[2946],{"nctId":1844,"briefTitle":1845,"status":110,"phases":2947,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2948,"interventions":2949},[90],[1851,1852,1853],[1821,1855,1856,1857,1858,1840],{"trials":2951,"activeCount":100},[],{"trials":2953,"activeCount":100},[],{"intervention":1857,"totalTrials":152,"cells":2955},{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2962,"PHASE4":2968,"NA":2970},{"trials":2957,"activeCount":100},[],{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[2964],{"nctId":1844,"briefTitle":1845,"status":110,"phases":2965,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2966,"interventions":2967},[90],[1851,1852,1853],[1821,1855,1856,1857,1858,1840],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[],{"intervention":1858,"totalTrials":152,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2978,"PHASE3":2980,"PHASE4":2986,"NA":2988},{"trials":2975,"activeCount":100},[],{"trials":2977,"activeCount":100},[],{"trials":2979,"activeCount":100},[],{"trials":2981,"activeCount":100},[2982],{"nctId":1844,"briefTitle":1845,"status":110,"phases":2983,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2984,"interventions":2985},[90],[1851,1852,1853],[1821,1855,1856,1857,1858,1840],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"intervention":2991,"totalTrials":152,"cells":2992},"DWP14012 X mg",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3014,"NA":3016},{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[],{"trials":3000,"activeCount":100},[3001],{"nctId":3002,"briefTitle":3003,"status":110,"phases":3004,"primaryCompletion":3005,"completion":2193,"start":3006,"enrollment":2369,"conditions":3007,"interventions":3010},"NCT04341454","Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis",[90],"2021-08-04","2020-06-02",[3008,3009],"Acute Gastritis","Chronic Gastritis",[2991,3011,3012,3013],"DWP14012 X mg placebo","DWP14012 Y mg","DWP14012 Y mg placebo",{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[],{"intervention":3011,"totalTrials":152,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3026,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[],{"trials":3027,"activeCount":100},[3028],{"nctId":3002,"briefTitle":3003,"status":110,"phases":3029,"primaryCompletion":3005,"completion":2193,"start":3006,"enrollment":2369,"conditions":3030,"interventions":3031},[90],[3008,3009],[2991,3011,3012,3013],{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[],{"intervention":3012,"totalTrials":152,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3044,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":100},[],{"trials":3043,"activeCount":100},[],{"trials":3045,"activeCount":100},[3046],{"nctId":3002,"briefTitle":3003,"status":110,"phases":3047,"primaryCompletion":3005,"completion":2193,"start":3006,"enrollment":2369,"conditions":3048,"interventions":3049},[90],[3008,3009],[2991,3011,3012,3013],{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"intervention":3013,"totalTrials":152,"cells":3055},{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3068,"NA":3070},{"trials":3057,"activeCount":100},[],{"trials":3059,"activeCount":100},[],{"trials":3061,"activeCount":100},[],{"trials":3063,"activeCount":100},[3064],{"nctId":3002,"briefTitle":3003,"status":110,"phases":3065,"primaryCompletion":3005,"completion":2193,"start":3006,"enrollment":2369,"conditions":3066,"interventions":3067},[90],[3008,3009],[2991,3011,3012,3013],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"intervention":121,"totalTrials":152,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3080,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[],{"trials":3081,"activeCount":100},[3082],{"nctId":108,"briefTitle":109,"status":110,"phases":3083,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":3084,"interventions":3085},[90],[117],[119,120,121,95],{"trials":3087,"activeCount":100},[],{"trials":3089,"activeCount":100},[],{"intervention":3091,"totalTrials":152,"cells":3092},"Metformin\u002FAtorvastatin 1500mg\u002F40mg, QD",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3113,"NA":3115},{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"trials":3100,"activeCount":100},[3101],{"nctId":3102,"briefTitle":3103,"status":110,"phases":3104,"primaryCompletion":3105,"completion":3105,"start":3106,"enrollment":3107,"conditions":3108,"interventions":3110},"NCT02947620","Metformin\u002FAtorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)",[90],"2017-02-27","2015-08",185,[3109,32],"Type II Diabetes",[3091,3111,3112],"Metformin 1500mg, QD","Atorvastatin 40mg, QD",{"trials":3114,"activeCount":100},[],{"trials":3116,"activeCount":100},[],{"intervention":3111,"totalTrials":152,"cells":3118},{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3125,"PHASE4":3131,"NA":3133},{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[3127],{"nctId":3102,"briefTitle":3103,"status":110,"phases":3128,"primaryCompletion":3105,"completion":3105,"start":3106,"enrollment":3107,"conditions":3129,"interventions":3130},[90],[3109,32],[3091,3111,3112],{"trials":3132,"activeCount":100},[],{"trials":3134,"activeCount":100},[],{"intervention":3112,"totalTrials":152,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3143,"PHASE4":3149,"NA":3151},{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[3145],{"nctId":3102,"briefTitle":3103,"status":110,"phases":3146,"primaryCompletion":3105,"completion":3105,"start":3106,"enrollment":3107,"conditions":3147,"interventions":3148},[90],[3109,32],[3091,3111,3112],{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"intervention":433,"totalTrials":152,"cells":3154},{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3167,"NA":3169},{"trials":3156,"activeCount":100},[],{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[3163],{"nctId":420,"briefTitle":421,"status":125,"phases":3164,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":3165,"interventions":3166},[90],[428,29,429,430,431],[263,345,246,433],{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[],{"intervention":630,"totalTrials":152,"cells":3172},{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3179,"PHASE4":3185,"NA":3187},{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":100},[],{"trials":3180,"activeCount":100},[3181],{"nctId":621,"briefTitle":622,"status":110,"phases":3182,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":3183,"interventions":3184},[90],[628],[630,631,632,591,633],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"intervention":631,"totalTrials":152,"cells":3190},{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3197,"PHASE4":3203,"NA":3205},{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[3199],{"nctId":621,"briefTitle":622,"status":110,"phases":3200,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":3201,"interventions":3202},[90],[628],[630,631,632,591,633],{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[],{"intervention":632,"totalTrials":152,"cells":3208},{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3221,"NA":3223},{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":100},[3217],{"nctId":621,"briefTitle":622,"status":110,"phases":3218,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":3219,"interventions":3220},[90],[628],[630,631,632,591,633],{"trials":3222,"activeCount":100},[],{"trials":3224,"activeCount":100},[],{"intervention":633,"totalTrials":152,"cells":3226},{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3233,"PHASE4":3239,"NA":3241},{"trials":3228,"activeCount":100},[],{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":100},[3235],{"nctId":621,"briefTitle":622,"status":110,"phases":3236,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":3237,"interventions":3238},[90],[628],[630,631,632,591,633],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"intervention":2103,"totalTrials":152,"cells":3244},{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3249,"PHASE3":3251,"PHASE4":3257,"NA":3259},{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[],{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":100},[3253],{"nctId":2094,"briefTitle":2095,"status":125,"phases":3254,"primaryCompletion":2097,"completion":2098,"start":350,"enrollment":2099,"conditions":3255,"interventions":3256},[90],[2101],[2072,2103,2072],{"trials":3258,"activeCount":100},[],{"trials":3260,"activeCount":100},[],{"intervention":2010,"totalTrials":152,"cells":3262},{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3269,"PHASE4":3275,"NA":3277},{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[3271],{"nctId":2001,"briefTitle":2002,"status":110,"phases":3272,"primaryCompletion":2004,"completion":2005,"start":2006,"enrollment":2007,"conditions":3273,"interventions":3274},[90],[20,32],[1979,2010,2011],{"trials":3276,"activeCount":100},[],{"trials":3278,"activeCount":100},[],{"intervention":2011,"totalTrials":152,"cells":3280},{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3287,"PHASE4":3293,"NA":3295},{"trials":3282,"activeCount":100},[],{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[3289],{"nctId":2001,"briefTitle":2002,"status":110,"phases":3290,"primaryCompletion":2004,"completion":2005,"start":2006,"enrollment":2007,"conditions":3291,"interventions":3292},[90],[20,32],[1979,2010,2011],{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[],{"intervention":3298,"totalTrials":152,"cells":3299},"DWJ1319",{"EARLY_PHASE1":3300,"PHASE1":3302,"PHASE2":3304,"PHASE3":3306,"PHASE4":3317,"NA":3319},{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[3308],{"nctId":3309,"briefTitle":3310,"status":110,"phases":3311,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":3314,"conditions":3315,"interventions":3316},"NCT02490111","Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer",[90],"2018-01","2015-05",521,[1311],[3298],{"trials":3318,"activeCount":100},[],{"trials":3320,"activeCount":100},[],{"intervention":3322,"totalTrials":152,"cells":3323},"Clostridium Botulinum Toxin Type A",{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3330,"PHASE4":3341,"NA":3343},{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[],{"trials":3331,"activeCount":100},[3332],{"nctId":3333,"briefTitle":3334,"status":110,"phases":3335,"primaryCompletion":3312,"completion":3312,"start":3336,"enrollment":3337,"conditions":3338,"interventions":3340},"NCT02947815","Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm",[89,90],"2016-10",234,[3339],"Blepharospasm",[3322,3322],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"intervention":134,"totalTrials":152,"cells":3346},{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3353,"PHASE4":3359,"NA":3361},{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[3355],{"nctId":123,"briefTitle":124,"status":125,"phases":3356,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":3357,"interventions":3358},[90],[132],[134,135,120,136],{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[],{"intervention":135,"totalTrials":152,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[],{"trials":3372,"activeCount":100},[3373],{"nctId":123,"briefTitle":124,"status":125,"phases":3374,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":3375,"interventions":3376},[90],[132],[134,135,120,136],{"trials":3378,"activeCount":100},[],{"trials":3380,"activeCount":100},[],{"intervention":3382,"totalTrials":35,"cells":3383},"DWRX2003",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3413,"PHASE3":3425,"PHASE4":3427,"NA":3429},{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[3388,3395,3404],{"nctId":3389,"briefTitle":3390,"status":125,"phases":3391,"primaryCompletion":3392,"completion":3392,"start":368,"enrollment":290,"conditions":3393,"interventions":3394},"NCT04524052","To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19",[88],"2020-12",[15],[3382],{"nctId":3396,"briefTitle":3397,"status":125,"phases":3398,"primaryCompletion":3399,"completion":566,"start":3400,"enrollment":321,"conditions":3401,"interventions":3403},"NCT04592835","To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003",[88],"2020-12-13","2020-10-19",[3402],"COVID-19 Patients",[3382],{"nctId":3405,"briefTitle":3406,"status":1965,"phases":3407,"primaryCompletion":3408,"completion":3409,"start":3410,"enrollment":615,"conditions":3411,"interventions":3412},"NCT04541485","To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)",[88],"2021-03-03","2021-03-23","2020-12-04",[3402],[3382],{"trials":3414,"activeCount":100},[3415],{"nctId":3416,"briefTitle":3417,"status":1965,"phases":3418,"primaryCompletion":3419,"completion":3420,"start":3421,"enrollment":152,"conditions":3422,"interventions":3424},"NCT05226533","Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.",[89],"2022-12-16","2022-12-21","2022-03-31",[3423],"COVID-19",[3382],{"trials":3426,"activeCount":100},[],{"trials":3428,"activeCount":100},[],{"trials":3430,"activeCount":100},[],{"intervention":3432,"totalTrials":96,"cells":3433},"DWP05195",{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3453,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[3438,3445],{"nctId":3439,"briefTitle":3440,"status":110,"phases":3441,"primaryCompletion":2168,"start":1684,"enrollment":277,"conditions":3442,"interventions":3444},"NCT01094834","A Multiple Dose Study of DWP05195 in Healthy Adult Subjects",[88],[3443],"Healthy Adult Volunteers",[3432],{"nctId":3446,"briefTitle":3447,"status":110,"phases":3448,"primaryCompletion":3449,"start":3450,"enrollment":1513,"conditions":3451,"interventions":3452},"NCT00969787","DWP05195 in Healthy Adult Male Volunteers",[88],"2009-11","2009-04",[15],[3432],{"trials":3454,"activeCount":100},[3455],{"nctId":3456,"briefTitle":3457,"status":110,"phases":3458,"primaryCompletion":3459,"completion":3460,"start":1990,"enrollment":440,"conditions":3461,"interventions":3463},"NCT01557010","Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia",[89],"2013-11","2013-12",[3462],"Postherpetic Neuralgia",[3432,3432,3432,3464],"Control",{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[],{"intervention":3472,"totalTrials":615,"cells":3473},"Esomeprazole",{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3487,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3475,"activeCount":100},[],{"trials":3477,"activeCount":100},[3478],{"nctId":3479,"briefTitle":3480,"status":110,"phases":3481,"primaryCompletion":3482,"completion":3482,"start":3483,"enrollment":3484,"conditions":3485,"interventions":3486},"NCT02757144","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers",[88],"2017-02","2016-03",120,[15],[1803,3472],{"trials":3488,"activeCount":100},[3489],{"nctId":3490,"briefTitle":3491,"status":110,"phases":3492,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":3495,"conditions":3496,"interventions":3498},"NCT03184324","Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)",[89],"2018-04-18","2017-08-28",211,[3497],"Erosive Gastroesophageal Reflux Disease",[1803,3472,3499,3500],"DWP14012 placebo","Esomeprazole placebo",{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[],{"intervention":2126,"totalTrials":152,"cells":3508},{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3513,"PHASE3":3519,"PHASE4":3521,"NA":3523},{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[3515],{"nctId":2118,"briefTitle":2119,"status":125,"phases":3516,"primaryCompletion":2121,"completion":2121,"start":2122,"enrollment":2123,"conditions":3517,"interventions":3518},[89],[1906],[2109,2126],{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[],{"intervention":3526,"totalTrials":152,"cells":3527},"DWP708",{"EARLY_PHASE1":3528,"PHASE1":3530,"PHASE2":3532,"PHASE3":3544,"PHASE4":3546,"NA":3548},{"trials":3529,"activeCount":100},[],{"trials":3531,"activeCount":100},[],{"trials":3533,"activeCount":100},[3534],{"nctId":3535,"briefTitle":3536,"status":110,"phases":3537,"primaryCompletion":3538,"completion":3539,"start":2660,"enrollment":3540,"conditions":3541,"interventions":3543},"NCT05378360","DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities",[89],"2023-12-05","2023-12-28",96,[3542],"Rash Acneiform",[3526],{"trials":3545,"activeCount":100},[],{"trials":3547,"activeCount":100},[],{"trials":3549,"activeCount":100},[],{"intervention":3464,"totalTrials":152,"cells":3551},{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":100},[3558],{"nctId":3456,"briefTitle":3457,"status":110,"phases":3559,"primaryCompletion":3459,"completion":3460,"start":1990,"enrollment":440,"conditions":3560,"interventions":3561},[89],[3462],[3432,3432,3432,3464],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"intervention":3499,"totalTrials":152,"cells":3569},{"EARLY_PHASE1":3570,"PHASE1":3572,"PHASE2":3574,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[],{"trials":3575,"activeCount":100},[3576],{"nctId":3490,"briefTitle":3491,"status":110,"phases":3577,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":3495,"conditions":3578,"interventions":3579},[89],[3497],[1803,3472,3499,3500],{"trials":3581,"activeCount":100},[],{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[],{"intervention":3500,"totalTrials":152,"cells":3587},{"EARLY_PHASE1":3588,"PHASE1":3590,"PHASE2":3592,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[],{"trials":3593,"activeCount":100},[3594],{"nctId":3490,"briefTitle":3491,"status":110,"phases":3595,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":3495,"conditions":3596,"interventions":3597},[89],[3497],[1803,3472,3499,3500],{"trials":3599,"activeCount":100},[],{"trials":3601,"activeCount":100},[],{"trials":3603,"activeCount":100},[],{"intervention":3605,"totalTrials":35,"cells":3606},"DWP14012 tablet A",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3648,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[3611,3621,3629,3640],{"nctId":3612,"briefTitle":3613,"status":125,"phases":3614,"primaryCompletion":3615,"completion":3616,"start":3617,"enrollment":321,"conditions":3618,"interventions":3619},"NCT04185805","Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (III)",[88],"2020-02-28","2020-04-30","2019-12-14",[15],[3605,3620],"DWP14012 tablet B",{"nctId":3622,"briefTitle":3623,"status":125,"phases":3624,"primaryCompletion":3625,"completion":3625,"start":3626,"enrollment":321,"conditions":3627,"interventions":3628},"NCT04003441","Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers",[88],"2019-08","2019-06",[15],[3605,3620],{"nctId":3630,"briefTitle":3631,"status":110,"phases":3632,"primaryCompletion":3633,"completion":3633,"start":3634,"enrollment":290,"conditions":3635,"interventions":3637},"NCT05149274","Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects",[88],"2021-10-26","2021-10-01",[3636],"Phase 1 Study, Healthy Volunteers",[3638,3639],"DWP14012 Tablet A","DWP14012 Tablet B",{"nctId":3641,"briefTitle":3642,"status":125,"phases":3643,"primaryCompletion":3644,"completion":370,"start":3645,"enrollment":321,"conditions":3646,"interventions":3647},"NCT04167267","Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (II)",[88],"2019-12","2019-11",[15],[3605,3620],{"trials":3649,"activeCount":100},[],{"trials":3651,"activeCount":100},[],{"trials":3653,"activeCount":100},[],{"trials":3655,"activeCount":100},[],{"intervention":3620,"totalTrials":35,"cells":3657},{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3678,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3659,"activeCount":100},[],{"trials":3661,"activeCount":100},[3662,3666,3670,3674],{"nctId":3612,"briefTitle":3613,"status":125,"phases":3663,"primaryCompletion":3615,"completion":3616,"start":3617,"enrollment":321,"conditions":3664,"interventions":3665},[88],[15],[3605,3620],{"nctId":3622,"briefTitle":3623,"status":125,"phases":3667,"primaryCompletion":3625,"completion":3625,"start":3626,"enrollment":321,"conditions":3668,"interventions":3669},[88],[15],[3605,3620],{"nctId":3630,"briefTitle":3631,"status":110,"phases":3671,"primaryCompletion":3633,"completion":3633,"start":3634,"enrollment":290,"conditions":3672,"interventions":3673},[88],[3636],[3638,3639],{"nctId":3641,"briefTitle":3642,"status":125,"phases":3675,"primaryCompletion":3644,"completion":370,"start":3645,"enrollment":321,"conditions":3676,"interventions":3677},[88],[15],[3605,3620],{"trials":3679,"activeCount":100},[],{"trials":3681,"activeCount":100},[],{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"intervention":3687,"totalTrials":96,"cells":3688},"Co-administration of DWC20155\u002FDWC20156",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[3693,3703,3713],{"nctId":3694,"briefTitle":3695,"status":110,"phases":3696,"primaryCompletion":3697,"completion":3698,"start":3699,"enrollment":16,"conditions":3700,"interventions":3701},"NCT02947139","Drug-Drug Interaction Study Between DWC20155 \u002F DWC20156 and DWC20161 in Healthy Volunteers",[88],"2016-10-24","2016-11-02","2016-09-29",[15],[3687,3702],"DWC20161",{"nctId":3704,"briefTitle":3705,"status":125,"phases":3706,"primaryCompletion":3707,"completion":3708,"start":3709,"enrollment":670,"conditions":3710,"interventions":3711},"NCT03005223","Drug-Drug Interaction Study Between DWC20155 \u002F DWC20156 and DWC20163 in Healthy Volunteers",[88],"2017-05","2017-06","2017-01-04",[15],[3687,3712],"DWC20163",{"nctId":3714,"briefTitle":3715,"status":110,"phases":3716,"primaryCompletion":1709,"completion":3717,"start":3718,"enrollment":1426,"conditions":3719,"interventions":3720},"NCT02952755","Drug-Drug Interaction Study Between DWC20155 \u002F DWC20156 and DWC20162 in Healthy Volunteers",[88],"2016-12-20","2016-11-28",[15],[3687,3721],"DWC20162",{"trials":3723,"activeCount":100},[],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[],{"intervention":3731,"totalTrials":615,"cells":3732},"Sarpogrelate HCL 300mg",{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3753,"PHASE3":3755,"PHASE4":3757,"NA":3759},{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[3737,3746],{"nctId":3738,"briefTitle":3739,"status":125,"phases":3740,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":3743,"conditions":3744,"interventions":3745},"NCT03947528","Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions",[88],"2019-05-13","2019-03-04",38,[15],[3731],{"nctId":3747,"briefTitle":3748,"status":110,"phases":3749,"primaryCompletion":3750,"completion":3750,"start":3742,"enrollment":3743,"conditions":3751,"interventions":3752},"NCT03947489","Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions",[88],"2019-05-06",[15],[3731],{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"trials":3760,"activeCount":100},[],{"intervention":1994,"totalTrials":615,"cells":3762},{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3781,"PHASE3":3783,"PHASE4":3785,"NA":3787},{"trials":3764,"activeCount":100},[],{"trials":3766,"activeCount":100},[3767,3771],{"nctId":1986,"briefTitle":1987,"status":110,"phases":3768,"primaryCompletion":1989,"completion":1990,"start":1511,"enrollment":1991,"conditions":3769,"interventions":3770},[88],[18],[1994,1995,1979],{"nctId":3772,"briefTitle":3773,"status":110,"phases":3774,"primaryCompletion":3775,"completion":3776,"start":3777,"enrollment":604,"conditions":3778,"interventions":3779},"NCT01415466","Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers",[88],"2011-09","2011-10","2011-08",[15],[1994,1995,3780],"Cresto, Olmetec",{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":100},[],{"trials":3788,"activeCount":100},[],{"intervention":1995,"totalTrials":615,"cells":3790},{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3803,"PHASE3":3805,"PHASE4":3807,"NA":3809},{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[3795,3799],{"nctId":1986,"briefTitle":1987,"status":110,"phases":3796,"primaryCompletion":1989,"completion":1990,"start":1511,"enrollment":1991,"conditions":3797,"interventions":3798},[88],[18],[1994,1995,1979],{"nctId":3772,"briefTitle":3773,"status":110,"phases":3800,"primaryCompletion":3775,"completion":3776,"start":3777,"enrollment":604,"conditions":3801,"interventions":3802},[88],[15],[1994,1995,3780],{"trials":3804,"activeCount":100},[],{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"intervention":3812,"totalTrials":615,"cells":3813},"DWP16001 drug A",{"EARLY_PHASE1":3814,"PHASE1":3816,"PHASE2":3839,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[3818,3827],{"nctId":3819,"briefTitle":3820,"status":110,"phases":3821,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":3743,"conditions":3824,"interventions":3825},"NCT05414591","Pharmacokinetics and Safety Following Administration of DWP16001",[88],"2021-08-01","2021-05-01",[15],[3812,3826],"DWP16001 drug B",{"nctId":3828,"briefTitle":3829,"status":110,"phases":3830,"primaryCompletion":3831,"completion":3832,"start":3833,"enrollment":3834,"conditions":3835,"interventions":3836},"NCT05465668","Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C",[88],"2022-08-16","2022-11-22","2022-07-22",43,[18],[3837,3838],"DWP16001 Drug A","DWP16001 Drug C",{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"intervention":3848,"totalTrials":615,"cells":3849},"DWP10292",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[3854,3863],{"nctId":3855,"briefTitle":3856,"status":110,"phases":3857,"primaryCompletion":2027,"completion":2027,"start":3313,"enrollment":1991,"conditions":3858,"interventions":3859},"NCT02622685","A Multiple Dose Study of DWP10292 and UDCA in Healthy Male Subjects",[88],[15],[3848,3860,3861,3862],"DWP10292 Placebo","Ursodeoxycholic acid","UDCA Placebo",{"nctId":3864,"briefTitle":3865,"status":110,"phases":3866,"primaryCompletion":1989,"completion":1989,"start":3777,"enrollment":670,"conditions":3867,"interventions":3868},"NCT01423526","A Single Dose Study of DWP10292 in Healthy Male Subjects",[88],[15],[3848],{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"intervention":3878,"totalTrials":615,"cells":3879},"Ursodiol 500 MG",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3901,"PHASE3":3903,"PHASE4":3905,"NA":3907},{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[3884,3893],{"nctId":3885,"briefTitle":3886,"status":110,"phases":3887,"primaryCompletion":1697,"completion":1697,"start":3888,"enrollment":3889,"conditions":3890,"interventions":3891},"NCT03512808","A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting Conditions",[88],"2017-06-01",77,[15],[3878,3892],"Urso Forte 500Mg",{"nctId":3894,"briefTitle":3895,"status":110,"phases":3896,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":3889,"conditions":3899,"interventions":3900},"NCT03512821","A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions",[88],"2017-11-30","2017-10-01",[15],[3878,3892],{"trials":3902,"activeCount":100},[],{"trials":3904,"activeCount":100},[],{"trials":3906,"activeCount":100},[],{"trials":3908,"activeCount":100},[],{"intervention":3892,"totalTrials":615,"cells":3910},{"EARLY_PHASE1":3911,"PHASE1":3913,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[3915,3919],{"nctId":3885,"briefTitle":3886,"status":110,"phases":3916,"primaryCompletion":1697,"completion":1697,"start":3888,"enrollment":3889,"conditions":3917,"interventions":3918},[88],[15],[3878,3892],{"nctId":3894,"briefTitle":3895,"status":110,"phases":3920,"primaryCompletion":3897,"completion":3897,"start":3898,"enrollment":3889,"conditions":3921,"interventions":3922},[88],[15],[3878,3892],{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[],{"intervention":3932,"totalTrials":615,"cells":3933},"DWJ1543",{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3953,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3935,"activeCount":100},[],{"trials":3937,"activeCount":100},[3938,3946],{"nctId":3939,"briefTitle":3940,"status":125,"phases":3941,"primaryCompletion":3942,"completion":3942,"start":2556,"enrollment":321,"conditions":3943,"interventions":3944},"NCT05954247","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 in Healthy Adult Volunteers",[88],"2023-12-01",[18],[3932,3945],"DWC202216",{"nctId":3947,"briefTitle":3948,"status":125,"phases":3949,"primaryCompletion":3942,"completion":3942,"start":2556,"enrollment":670,"conditions":3950,"interventions":3951},"NCT05954338","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 With DWC202307 in Healthy Adult Volunteers",[88],[18],[3952,3932,3945],"DWC202307",{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"trials":3958,"activeCount":100},[],{"trials":3960,"activeCount":100},[],{"intervention":3945,"totalTrials":615,"cells":3962},{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3975,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[3967,3971],{"nctId":3939,"briefTitle":3940,"status":125,"phases":3968,"primaryCompletion":3942,"completion":3942,"start":2556,"enrollment":321,"conditions":3969,"interventions":3970},[88],[18],[3932,3945],{"nctId":3947,"briefTitle":3948,"status":125,"phases":3972,"primaryCompletion":3942,"completion":3942,"start":2556,"enrollment":670,"conditions":3973,"interventions":3974},[88],[18],[3952,3932,3945],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[],{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"intervention":3984,"totalTrials":615,"cells":3985},"Co-administration of DWC20155 and DWC20156",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":4009,"PHASE3":4011,"PHASE4":4013,"NA":4015},{"trials":3987,"activeCount":100},[],{"trials":3989,"activeCount":100},[3990,3999],{"nctId":3991,"briefTitle":3992,"status":125,"phases":3993,"primaryCompletion":3994,"start":2027,"enrollment":3995,"conditions":3996,"interventions":3997},"NCT03016494","Safety and Pharmacokinetics Study of Fixed Dose Combination of DWJ1386 Compared With Co-administration of DWC20155 and DWC20156 in Healthy Subjects",[88],"2017-03",56,[15],[3984,3998],"DWJ1386 Tab.",{"nctId":4000,"briefTitle":4001,"status":110,"phases":4002,"primaryCompletion":4003,"completion":4004,"start":4005,"enrollment":670,"conditions":4006,"interventions":4007},"NCT02952547","Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects",[88],"2016-11-26","2017-01-10","2016-10-30",[15],[3984,4008],"DWJ1366 Tab.",{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"intervention":4018,"totalTrials":615,"cells":4019},"DWJ1351",{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4021,"activeCount":100},[],{"trials":4023,"activeCount":100},[4024,4033],{"nctId":4025,"briefTitle":4026,"status":125,"phases":4027,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":1991,"conditions":4030,"interventions":4031},"NCT02665832","Study of DWJ1351 in Healthy Male Volunteers",[88],"2016-06","2016-01",[15],[4018,4032],"Co-administration of Sevikar",{"nctId":4034,"briefTitle":4035,"status":110,"phases":4036,"primaryCompletion":4037,"completion":4038,"start":4039,"enrollment":4040,"conditions":4041,"interventions":4042},"NCT03753477","Clinical Trial to Investigate the Efficacy and Safety of DWJ1351",[88],"2018-01-26","2018-02-01","2017-12-22",64,[15],[4018,4043],"Sevikar and Crestor",{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[],{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"intervention":4053,"totalTrials":615,"cells":4054},"Anpl-one SR Tab. 300mg",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4076,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[4059,4069],{"nctId":4060,"briefTitle":4061,"status":110,"phases":4062,"primaryCompletion":4063,"completion":4064,"start":4065,"enrollment":555,"conditions":4066,"interventions":4067},"NCT03574285","A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions",[88],"2018-08-21","2018-10-12","2018-05-31",[15],[4053,4068],"Sarpodipil SR Tab. 300mg",{"nctId":4070,"briefTitle":4071,"status":110,"phases":4072,"primaryCompletion":4063,"completion":4064,"start":4065,"enrollment":4073,"conditions":4074,"interventions":4075},"NCT03573622","A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions",[88],62,[15],[4053,4068],{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"intervention":4068,"totalTrials":615,"cells":4085},{"EARLY_PHASE1":4086,"PHASE1":4088,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":100},[4090,4094],{"nctId":4060,"briefTitle":4061,"status":110,"phases":4091,"primaryCompletion":4063,"completion":4064,"start":4065,"enrollment":555,"conditions":4092,"interventions":4093},[88],[15],[4053,4068],{"nctId":4070,"briefTitle":4071,"status":110,"phases":4095,"primaryCompletion":4063,"completion":4064,"start":4065,"enrollment":4073,"conditions":4096,"interventions":4097},[88],[15],[4053,4068],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"intervention":558,"totalTrials":152,"cells":4107},{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4116,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4109,"activeCount":100},[],{"trials":4111,"activeCount":100},[4112],{"nctId":549,"briefTitle":550,"status":110,"phases":4113,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":4114,"interventions":4115},[88],[34],[542,558,559],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"intervention":559,"totalTrials":152,"cells":4125},{"EARLY_PHASE1":4126,"PHASE1":4128,"PHASE2":4134,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4127,"activeCount":100},[],{"trials":4129,"activeCount":100},[4130],{"nctId":549,"briefTitle":550,"status":110,"phases":4131,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":4132,"interventions":4133},[88],[34],[542,558,559],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"intervention":281,"totalTrials":152,"cells":4143},{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4152,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[4148],{"nctId":271,"briefTitle":272,"status":125,"phases":4149,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":4150,"interventions":4151},[88],[279,29],[281,282,263],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[],{"trials":4159,"activeCount":100},[],{"intervention":282,"totalTrials":152,"cells":4161},{"EARLY_PHASE1":4162,"PHASE1":4164,"PHASE2":4170,"PHASE3":4172,"PHASE4":4174,"NA":4176},{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[4166],{"nctId":271,"briefTitle":272,"status":125,"phases":4167,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":4168,"interventions":4169},[88],[279,29],[281,282,263],{"trials":4171,"activeCount":100},[],{"trials":4173,"activeCount":100},[],{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"intervention":4179,"totalTrials":152,"cells":4180},"DWP14012 Amg",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4197,"PHASE3":4199,"PHASE4":4201,"NA":4203},{"trials":4182,"activeCount":100},[],{"trials":4184,"activeCount":100},[4185],{"nctId":4186,"briefTitle":4187,"status":110,"phases":4188,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":555,"conditions":4191,"interventions":4192},"NCT03487562","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects",[88],"2019-01-11","2018-04-08",[15],[4179,4193,4194,4195,4196],"DWP14012 Bmg","Clarithromycin","Amoxicillin","Lansoprazole",{"trials":4198,"activeCount":100},[],{"trials":4200,"activeCount":100},[],{"trials":4202,"activeCount":100},[],{"trials":4204,"activeCount":100},[],{"intervention":4193,"totalTrials":152,"cells":4206},{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4215,"PHASE3":4217,"PHASE4":4219,"NA":4221},{"trials":4208,"activeCount":100},[],{"trials":4210,"activeCount":100},[4211],{"nctId":4186,"briefTitle":4187,"status":110,"phases":4212,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":555,"conditions":4213,"interventions":4214},[88],[15],[4179,4193,4194,4195,4196],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[],{"trials":4220,"activeCount":100},[],{"trials":4222,"activeCount":100},[],{"intervention":4194,"totalTrials":152,"cells":4224},{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4233,"PHASE3":4235,"PHASE4":4237,"NA":4239},{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[4229],{"nctId":4186,"briefTitle":4187,"status":110,"phases":4230,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":555,"conditions":4231,"interventions":4232},[88],[15],[4179,4193,4194,4195,4196],{"trials":4234,"activeCount":100},[],{"trials":4236,"activeCount":100},[],{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[],{"intervention":4195,"totalTrials":152,"cells":4242},{"EARLY_PHASE1":4243,"PHASE1":4245,"PHASE2":4251,"PHASE3":4253,"PHASE4":4255,"NA":4257},{"trials":4244,"activeCount":100},[],{"trials":4246,"activeCount":100},[4247],{"nctId":4186,"briefTitle":4187,"status":110,"phases":4248,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":555,"conditions":4249,"interventions":4250},[88],[15],[4179,4193,4194,4195,4196],{"trials":4252,"activeCount":100},[],{"trials":4254,"activeCount":100},[],{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[],{"intervention":4196,"totalTrials":152,"cells":4260},{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4269,"PHASE3":4271,"PHASE4":4273,"NA":4275},{"trials":4262,"activeCount":100},[],{"trials":4264,"activeCount":100},[4265],{"nctId":4186,"briefTitle":4187,"status":110,"phases":4266,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":555,"conditions":4267,"interventions":4268},[88],[15],[4179,4193,4194,4195,4196],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[],{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[],{"intervention":4278,"totalTrials":152,"cells":4279},"DWP09031",{"EARLY_PHASE1":4280,"PHASE1":4282,"PHASE2":4291,"PHASE3":4293,"PHASE4":4295,"NA":4297},{"trials":4281,"activeCount":100},[],{"trials":4283,"activeCount":100},[4284],{"nctId":4285,"briefTitle":4286,"status":1965,"phases":4287,"primaryCompletion":2004,"completion":3460,"start":1511,"enrollment":4288,"conditions":4289,"interventions":4290},"NCT01522586","Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031",[88],74,[15],[4278],{"trials":4292,"activeCount":100},[],{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"intervention":4300,"totalTrials":152,"cells":4301},"Ursodeoxycholic Acid 250 Mg Oral",{"EARLY_PHASE1":4302,"PHASE1":4304,"PHASE2":4316,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[4306],{"nctId":4307,"briefTitle":4308,"status":110,"phases":4309,"primaryCompletion":4310,"completion":4310,"start":4311,"enrollment":4312,"conditions":4313,"interventions":4315},"NCT05832697","An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers",[88],"2023-01-30","2022-01-27",44,[4314],"Healthy Subject",[4300],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"intervention":302,"totalTrials":152,"cells":4325},{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4334,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[4330],{"nctId":294,"briefTitle":295,"status":110,"phases":4331,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":4332,"interventions":4333},[88],[15],[302,263,303],{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[],{"intervention":303,"totalTrials":152,"cells":4343},{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4352,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4345,"activeCount":100},[],{"trials":4347,"activeCount":100},[4348],{"nctId":294,"briefTitle":295,"status":110,"phases":4349,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":4350,"interventions":4351},[88],[15],[302,263,303],{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"intervention":4361,"totalTrials":152,"cells":4362},"Diet A group",{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4378,"PHASE3":4380,"PHASE4":4382,"NA":4384},{"trials":4364,"activeCount":100},[],{"trials":4366,"activeCount":100},[4367],{"nctId":4368,"briefTitle":4369,"status":110,"phases":4370,"primaryCompletion":4371,"completion":4372,"start":4373,"enrollment":604,"conditions":4374,"interventions":4375},"NCT04767815","To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers",[88],"2021-05-31","2021-06-04","2021-03-22",[34],[4361,4376,4377],"Diet B group","Diet C group",{"trials":4379,"activeCount":100},[],{"trials":4381,"activeCount":100},[],{"trials":4383,"activeCount":100},[],{"trials":4385,"activeCount":100},[],{"intervention":4376,"totalTrials":152,"cells":4387},{"EARLY_PHASE1":4388,"PHASE1":4390,"PHASE2":4396,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[4392],{"nctId":4368,"briefTitle":4369,"status":110,"phases":4393,"primaryCompletion":4371,"completion":4372,"start":4373,"enrollment":604,"conditions":4394,"interventions":4395},[88],[34],[4361,4376,4377],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[],{"trials":4403,"activeCount":100},[],{"intervention":4377,"totalTrials":152,"cells":4405},{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4414,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4407,"activeCount":100},[],{"trials":4409,"activeCount":100},[4410],{"nctId":4368,"briefTitle":4369,"status":110,"phases":4411,"primaryCompletion":4371,"completion":4372,"start":4373,"enrollment":604,"conditions":4412,"interventions":4413},[88],[34],[4361,4376,4377],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[],{"trials":4419,"activeCount":100},[],{"trials":4421,"activeCount":100},[],{"intervention":4423,"totalTrials":152,"cells":4424},"DWJ1230",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4439,"PHASE3":4441,"PHASE4":4443,"NA":4445},{"trials":4426,"activeCount":100},[],{"trials":4428,"activeCount":100},[4429],{"nctId":4430,"briefTitle":4431,"status":110,"phases":4432,"primaryCompletion":1258,"completion":4433,"start":4434,"enrollment":826,"conditions":4435,"interventions":4437},"NCT05816681","Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.",[88],"2023-04-10","2022-08-22",[4436],"Diarrhea",[4423,4438],"DWB2001",{"trials":4440,"activeCount":100},[],{"trials":4442,"activeCount":100},[],{"trials":4444,"activeCount":100},[],{"trials":4446,"activeCount":100},[],{"intervention":4438,"totalTrials":152,"cells":4448},{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4457,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[4453],{"nctId":4430,"briefTitle":4431,"status":110,"phases":4454,"primaryCompletion":1258,"completion":4433,"start":4434,"enrollment":826,"conditions":4455,"interventions":4456},[88],[4436],[4423,4438],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[],{"trials":4464,"activeCount":100},[],{"intervention":312,"totalTrials":152,"cells":4466},{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[4471],{"nctId":305,"briefTitle":306,"status":125,"phases":4472,"primaryCompletion":308,"completion":308,"start":309,"enrollment":227,"conditions":4473,"interventions":4474},[88],[15],[263,312,313],{"trials":4476,"activeCount":100},[],{"trials":4478,"activeCount":100},[],{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[],{"intervention":313,"totalTrials":152,"cells":4484},{"EARLY_PHASE1":4485,"PHASE1":4487,"PHASE2":4493,"PHASE3":4495,"PHASE4":4497,"NA":4499},{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[4489],{"nctId":305,"briefTitle":306,"status":125,"phases":4490,"primaryCompletion":308,"completion":308,"start":309,"enrollment":227,"conditions":4491,"interventions":4492},[88],[15],[263,312,313],{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"intervention":3826,"totalTrials":152,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4511,"PHASE3":4513,"PHASE4":4515,"NA":4517},{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[4507],{"nctId":3819,"briefTitle":3820,"status":110,"phases":4508,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":3743,"conditions":4509,"interventions":4510},[88],[15],[3812,3826],{"trials":4512,"activeCount":100},[],{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":100},[],{"trials":4518,"activeCount":100},[],{"intervention":3702,"totalTrials":152,"cells":4520},{"EARLY_PHASE1":4521,"PHASE1":4523,"PHASE2":4529,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4522,"activeCount":100},[],{"trials":4524,"activeCount":100},[4525],{"nctId":3694,"briefTitle":3695,"status":110,"phases":4526,"primaryCompletion":3697,"completion":3698,"start":3699,"enrollment":16,"conditions":4527,"interventions":4528},[88],[15],[3687,3702],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[],{"trials":4536,"activeCount":100},[],{"intervention":4538,"totalTrials":152,"cells":4539},"DWJ1445",{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4555,"PHASE3":4557,"PHASE4":4559,"NA":4561},{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[4544],{"nctId":4545,"briefTitle":4546,"status":110,"phases":4547,"primaryCompletion":4548,"completion":4549,"start":4550,"enrollment":4551,"conditions":4552,"interventions":4553},"NCT07256600","PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers",[88],"2025-11-23","2025-12-02","2025-11-14",70,[828],[4538,4554],"DWC202506",{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"intervention":4554,"totalTrials":152,"cells":4564},{"EARLY_PHASE1":4565,"PHASE1":4567,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4566,"activeCount":100},[],{"trials":4568,"activeCount":100},[4569],{"nctId":4545,"briefTitle":4546,"status":110,"phases":4570,"primaryCompletion":4548,"completion":4549,"start":4550,"enrollment":4551,"conditions":4571,"interventions":4572},[88],[828],[4538,4554],{"trials":4574,"activeCount":100},[],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"intervention":3860,"totalTrials":152,"cells":4582},{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4584,"activeCount":100},[],{"trials":4586,"activeCount":100},[4587],{"nctId":3855,"briefTitle":3856,"status":110,"phases":4588,"primaryCompletion":2027,"completion":2027,"start":3313,"enrollment":1991,"conditions":4589,"interventions":4590},[88],[15],[3848,3860,3861,3862],{"trials":4592,"activeCount":100},[],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"intervention":3861,"totalTrials":152,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4609,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[4605],{"nctId":3855,"briefTitle":3856,"status":110,"phases":4606,"primaryCompletion":2027,"completion":2027,"start":3313,"enrollment":1991,"conditions":4607,"interventions":4608},[88],[15],[3848,3860,3861,3862],{"trials":4610,"activeCount":100},[],{"trials":4612,"activeCount":100},[],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"intervention":3862,"totalTrials":152,"cells":4618},{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[4623],{"nctId":3855,"briefTitle":3856,"status":110,"phases":4624,"primaryCompletion":2027,"completion":2027,"start":3313,"enrollment":1991,"conditions":4625,"interventions":4626},[88],[15],[3848,3860,3861,3862],{"trials":4628,"activeCount":100},[],{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"intervention":4636,"totalTrials":152,"cells":4637},"DWC202313",{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4651,"PHASE3":4653,"PHASE4":4655,"NA":4657},{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[4642],{"nctId":4643,"briefTitle":4644,"status":125,"phases":4645,"primaryCompletion":2411,"completion":2411,"start":4646,"enrollment":290,"conditions":4647,"interventions":4649},"NCT06119958","Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects",[88],"2023-10-27",[4648],"Drug Drug Interaction",[4636,4650],"DWC202314",{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[],{"trials":4658,"activeCount":100},[],{"intervention":4650,"totalTrials":152,"cells":4660},{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4669,"PHASE3":4671,"PHASE4":4673,"NA":4675},{"trials":4662,"activeCount":100},[],{"trials":4664,"activeCount":100},[4665],{"nctId":4643,"briefTitle":4644,"status":125,"phases":4666,"primaryCompletion":2411,"completion":2411,"start":4646,"enrollment":290,"conditions":4667,"interventions":4668},[88],[4648],[4636,4650],{"trials":4670,"activeCount":100},[],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"intervention":4678,"totalTrials":152,"cells":4679},"DWC202201",{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4693,"PHASE3":4695,"PHASE4":4697,"NA":4699},{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[4684],{"nctId":4685,"briefTitle":4686,"status":125,"phases":4687,"primaryCompletion":4688,"completion":4689,"start":4690,"enrollment":604,"conditions":4691,"interventions":4692},"NCT05812404","Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects",[88],"2023-03-28","2023-06-16","2022-10-26",[4648],[1803,4678],{"trials":4694,"activeCount":100},[],{"trials":4696,"activeCount":100},[],{"trials":4698,"activeCount":100},[],{"trials":4700,"activeCount":100},[],{"intervention":333,"totalTrials":152,"cells":4702},{"EARLY_PHASE1":4703,"PHASE1":4705,"PHASE2":4711,"PHASE3":4713,"PHASE4":4715,"NA":4717},{"trials":4704,"activeCount":100},[],{"trials":4706,"activeCount":100},[4707],{"nctId":325,"briefTitle":326,"status":110,"phases":4708,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":4709,"interventions":4710},[88],[15],[263,333,334],{"trials":4712,"activeCount":100},[],{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"intervention":334,"totalTrials":152,"cells":4720},{"EARLY_PHASE1":4721,"PHASE1":4723,"PHASE2":4729,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[4725],{"nctId":325,"briefTitle":326,"status":110,"phases":4726,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":4727,"interventions":4728},[88],[15],[263,333,334],{"trials":4730,"activeCount":100},[],{"trials":4732,"activeCount":100},[],{"trials":4734,"activeCount":100},[],{"trials":4736,"activeCount":100},[],{"intervention":4738,"totalTrials":152,"cells":4739},"DWC202202",{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4753,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4741,"activeCount":100},[],{"trials":4743,"activeCount":100},[4744],{"nctId":4745,"briefTitle":4746,"status":110,"phases":4747,"primaryCompletion":4748,"completion":4748,"start":4749,"enrollment":604,"conditions":4750,"interventions":4751},"NCT05574374","Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects",[88],"2023-03-06","2022-09-21",[4648],[1803,4738,4752],"DWC202203",{"trials":4754,"activeCount":100},[],{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"intervention":4752,"totalTrials":152,"cells":4762},{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":100},[4767],{"nctId":4745,"briefTitle":4746,"status":110,"phases":4768,"primaryCompletion":4748,"completion":4748,"start":4749,"enrollment":604,"conditions":4769,"interventions":4770},[88],[4648],[1803,4738,4752],{"trials":4772,"activeCount":100},[],{"trials":4774,"activeCount":100},[],{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[],{"intervention":4780,"totalTrials":152,"cells":4781},"DWC20141",{"EARLY_PHASE1":4782,"PHASE1":4784,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4783,"activeCount":100},[],{"trials":4785,"activeCount":100},[4786],{"nctId":4787,"briefTitle":4788,"status":110,"phases":4789,"primaryCompletion":1666,"completion":4790,"start":4791,"enrollment":1685,"conditions":4792,"interventions":4793},"NCT02369302","Pharmacokinetics and Drug Interaction Study Between DWC20141 and DWC20142 in Healthy Male Volunteers",[88],"2015-06","2015-01",[15],[4780,4794,4795],"DWC20142","DWC20141, DWC20142",{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[],{"intervention":4794,"totalTrials":152,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4814,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4807,"activeCount":100},[],{"trials":4809,"activeCount":100},[4810],{"nctId":4787,"briefTitle":4788,"status":110,"phases":4811,"primaryCompletion":1666,"completion":4790,"start":4791,"enrollment":1685,"conditions":4812,"interventions":4813},[88],[15],[4780,4794,4795],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"trials":4821,"activeCount":100},[],{"intervention":4795,"totalTrials":152,"cells":4823},{"EARLY_PHASE1":4824,"PHASE1":4826,"PHASE2":4832,"PHASE3":4834,"PHASE4":4836,"NA":4838},{"trials":4825,"activeCount":100},[],{"trials":4827,"activeCount":100},[4828],{"nctId":4787,"briefTitle":4788,"status":110,"phases":4829,"primaryCompletion":1666,"completion":4790,"start":4791,"enrollment":1685,"conditions":4830,"interventions":4831},[88],[15],[4780,4794,4795],{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[],{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":100},[],{"intervention":4841,"totalTrials":152,"cells":4842},"Sevikar",{"EARLY_PHASE1":4843,"PHASE1":4845,"PHASE2":4855,"PHASE3":4857,"PHASE4":4859,"NA":4861},{"trials":4844,"activeCount":100},[],{"trials":4846,"activeCount":100},[4847],{"nctId":4848,"briefTitle":4849,"status":110,"phases":4850,"primaryCompletion":4851,"completion":4851,"start":2133,"enrollment":290,"conditions":4852,"interventions":4853},"NCT02089399","Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers",[88],"2014-06",[15],[4841,4854],"crestor",{"trials":4856,"activeCount":100},[],{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[],{"trials":4862,"activeCount":100},[],{"intervention":4854,"totalTrials":152,"cells":4864},{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4873,"PHASE3":4875,"PHASE4":4877,"NA":4879},{"trials":4866,"activeCount":100},[],{"trials":4868,"activeCount":100},[4869],{"nctId":4848,"briefTitle":4849,"status":110,"phases":4870,"primaryCompletion":4851,"completion":4851,"start":2133,"enrollment":290,"conditions":4871,"interventions":4872},[88],[15],[4841,4854],{"trials":4874,"activeCount":100},[],{"trials":4876,"activeCount":100},[],{"trials":4878,"activeCount":100},[],{"trials":4880,"activeCount":100},[],{"intervention":4882,"totalTrials":152,"cells":4883},"DWP422 25mg",{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4896,"PHASE3":4898,"PHASE4":4900,"NA":4902},{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[4888],{"nctId":4889,"briefTitle":4890,"status":125,"phases":4891,"primaryCompletion":1512,"completion":1512,"start":2006,"enrollment":3743,"conditions":4892,"interventions":4894},"NCT01635686","Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers",[88],[4893],"Rheumatoid Arthritis",[4882,4895],"ENBREL 25MG PFS INJ.",{"trials":4897,"activeCount":100},[],{"trials":4899,"activeCount":100},[],{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[],{"intervention":4895,"totalTrials":152,"cells":4905},{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4914,"PHASE3":4916,"PHASE4":4918,"NA":4920},{"trials":4907,"activeCount":100},[],{"trials":4909,"activeCount":100},[4910],{"nctId":4889,"briefTitle":4890,"status":125,"phases":4911,"primaryCompletion":1512,"completion":1512,"start":2006,"enrollment":3743,"conditions":4912,"interventions":4913},[88],[4893],[4882,4895],{"trials":4915,"activeCount":100},[],{"trials":4917,"activeCount":100},[],{"trials":4919,"activeCount":100},[],{"trials":4921,"activeCount":100},[],{"intervention":1927,"totalTrials":152,"cells":4923},{"EARLY_PHASE1":4924,"PHASE1":4926,"PHASE2":4932,"PHASE3":4934,"PHASE4":4936,"NA":4938},{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[4928],{"nctId":1919,"briefTitle":1920,"status":110,"phases":4929,"primaryCompletion":423,"completion":1922,"start":1923,"enrollment":1924,"conditions":4930,"interventions":4931},[88],[516],[1927,1928],{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[],{"trials":4939,"activeCount":100},[],{"intervention":4941,"totalTrials":152,"cells":4942},"DWP213388",{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4956,"PHASE3":4958,"PHASE4":4960,"NA":4962},{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[4947],{"nctId":4948,"briefTitle":4949,"status":4950,"phases":4951,"primaryCompletion":4952,"completion":2854,"start":4953,"enrollment":100,"conditions":4954,"interventions":4955},"NCT05607589","The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects","WITHDRAWN",[88],"2024-02-20","2022-10",[15],[4941],{"trials":4957,"activeCount":100},[],{"trials":4959,"activeCount":100},[],{"trials":4961,"activeCount":100},[],{"trials":4963,"activeCount":100},[],{"intervention":1802,"totalTrials":152,"cells":4965},{"EARLY_PHASE1":4966,"PHASE1":4968,"PHASE2":4974,"PHASE3":4976,"PHASE4":4978,"NA":4980},{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[4970],{"nctId":1795,"briefTitle":1796,"status":125,"phases":4971,"primaryCompletion":566,"completion":1798,"start":1799,"enrollment":604,"conditions":4972,"interventions":4973},[88],[15],[1772,1802,1803],{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[],{"trials":4979,"activeCount":100},[],{"trials":4981,"activeCount":100},[],{"intervention":3780,"totalTrials":152,"cells":4983},{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4992,"PHASE3":4994,"PHASE4":4996,"NA":4998},{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[4988],{"nctId":3772,"briefTitle":3773,"status":110,"phases":4989,"primaryCompletion":3775,"completion":3776,"start":3777,"enrollment":604,"conditions":4990,"interventions":4991},[88],[15],[1994,1995,3780],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[],{"trials":4997,"activeCount":100},[],{"trials":4999,"activeCount":100},[],{"intervention":3998,"totalTrials":152,"cells":5001},{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5010,"PHASE3":5012,"PHASE4":5014,"NA":5016},{"trials":5003,"activeCount":100},[],{"trials":5005,"activeCount":100},[5006],{"nctId":3991,"briefTitle":3992,"status":125,"phases":5007,"primaryCompletion":3994,"start":2027,"enrollment":3995,"conditions":5008,"interventions":5009},[88],[15],[3984,3998],{"trials":5011,"activeCount":100},[],{"trials":5013,"activeCount":100},[],{"trials":5015,"activeCount":100},[],{"trials":5017,"activeCount":100},[],{"intervention":5019,"totalTrials":152,"cells":5020},"DWJ1392",{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5034,"PHASE3":5036,"PHASE4":5038,"NA":5040},{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":100},[5025],{"nctId":5026,"briefTitle":5027,"status":125,"phases":5028,"primaryCompletion":5029,"completion":3994,"start":5030,"enrollment":1241,"conditions":5031,"interventions":5032},"NCT03016520","Pharmacokinetics and Safety Study of DWJ1392 and DWC20164 in Healthy Male Volunteers",[88],"2017-01-26","2017-01-09",[15],[5019,5033],"DWC20164",{"trials":5035,"activeCount":100},[],{"trials":5037,"activeCount":100},[],{"trials":5039,"activeCount":100},[],{"trials":5041,"activeCount":100},[],{"intervention":5033,"totalTrials":152,"cells":5043},{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5052,"PHASE3":5054,"PHASE4":5056,"NA":5058},{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[5048],{"nctId":5026,"briefTitle":5027,"status":125,"phases":5049,"primaryCompletion":5029,"completion":3994,"start":5030,"enrollment":1241,"conditions":5050,"interventions":5051},[88],[15],[5019,5033],{"trials":5053,"activeCount":100},[],{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":100},[],{"trials":5059,"activeCount":100},[],{"intervention":5061,"totalTrials":152,"cells":5062},"[14C]DWP14012",{"EARLY_PHASE1":5063,"PHASE1":5065,"PHASE2":5075,"PHASE3":5077,"PHASE4":5079,"NA":5081},{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[5067],{"nctId":5068,"briefTitle":5069,"status":125,"phases":5070,"primaryCompletion":287,"completion":5071,"start":5072,"enrollment":24,"conditions":5073,"interventions":5074},"NCT05868967","A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects",[88],"2023-10-31","2023-02-27",[3636],[5061],{"trials":5076,"activeCount":100},[],{"trials":5078,"activeCount":100},[],{"trials":5080,"activeCount":100},[],{"trials":5082,"activeCount":100},[],{"intervention":5084,"totalTrials":152,"cells":5085},"Leuprolide Acetate",{"EARLY_PHASE1":5086,"PHASE1":5088,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5104},{"trials":5087,"activeCount":100},[],{"trials":5089,"activeCount":100},[5090],{"nctId":5091,"briefTitle":5092,"status":125,"phases":5093,"primaryCompletion":5094,"start":3482,"enrollment":4312,"conditions":5095,"interventions":5097},"NCT03029533","Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer",[88],"2017-11",[5096],"Prostate Cancer",[5084,5084],{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[],{"trials":5105,"activeCount":100},[],{"intervention":354,"totalTrials":152,"cells":5107},{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5116,"PHASE3":5118,"PHASE4":5120,"NA":5122},{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[5112],{"nctId":347,"briefTitle":348,"status":110,"phases":5113,"primaryCompletion":350,"completion":350,"start":351,"enrollment":227,"conditions":5114,"interventions":5115},[88],[15],[263,354,355],{"trials":5117,"activeCount":100},[],{"trials":5119,"activeCount":100},[],{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[],{"intervention":355,"totalTrials":152,"cells":5125},{"EARLY_PHASE1":5126,"PHASE1":5128,"PHASE2":5134,"PHASE3":5136,"PHASE4":5138,"NA":5140},{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[5130],{"nctId":347,"briefTitle":348,"status":110,"phases":5131,"primaryCompletion":350,"completion":350,"start":351,"enrollment":227,"conditions":5132,"interventions":5133},[88],[15],[263,354,355],{"trials":5135,"activeCount":100},[],{"trials":5137,"activeCount":100},[],{"trials":5139,"activeCount":100},[],{"trials":5141,"activeCount":100},[],{"intervention":3838,"totalTrials":152,"cells":5143},{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5152,"PHASE3":5154,"PHASE4":5156,"NA":5158},{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[5148],{"nctId":3828,"briefTitle":3829,"status":110,"phases":5149,"primaryCompletion":3831,"completion":3832,"start":3833,"enrollment":3834,"conditions":5150,"interventions":5151},[88],[18],[3837,3838],{"trials":5153,"activeCount":100},[],{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"intervention":4032,"totalTrials":152,"cells":5161},{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5170,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[5166],{"nctId":4025,"briefTitle":4026,"status":125,"phases":5167,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":1991,"conditions":5168,"interventions":5169},[88],[15],[4018,4032],{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"intervention":3952,"totalTrials":152,"cells":5179},{"EARLY_PHASE1":5180,"PHASE1":5182,"PHASE2":5188,"PHASE3":5190,"PHASE4":5192,"NA":5194},{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[5184],{"nctId":3947,"briefTitle":3948,"status":125,"phases":5185,"primaryCompletion":3942,"completion":3942,"start":2556,"enrollment":670,"conditions":5186,"interventions":5187},[88],[18],[3952,3932,3945],{"trials":5189,"activeCount":100},[],{"trials":5191,"activeCount":100},[],{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"intervention":5197,"totalTrials":152,"cells":5198},"DWC202211 100mg",{"EARLY_PHASE1":5199,"PHASE1":5201,"PHASE2":5215,"PHASE3":5217,"PHASE4":5219,"NA":5221},{"trials":5200,"activeCount":100},[],{"trials":5202,"activeCount":100},[5203],{"nctId":5204,"briefTitle":5205,"status":125,"phases":5206,"primaryCompletion":5207,"completion":5208,"start":5209,"enrollment":321,"conditions":5210,"interventions":5212},"NCT05699070","Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects",[88],"2023-04-24","2023-06-01","2023-02-15",[5211],"Drug-drug Interaction",[5197,5213,5214],"DWC202212 5mg","DWC202211 100mg + DWC202212 5mg",{"trials":5216,"activeCount":100},[],{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"trials":5222,"activeCount":100},[],{"intervention":5213,"totalTrials":152,"cells":5224},{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5233,"PHASE3":5235,"PHASE4":5237,"NA":5239},{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[5229],{"nctId":5204,"briefTitle":5205,"status":125,"phases":5230,"primaryCompletion":5207,"completion":5208,"start":5209,"enrollment":321,"conditions":5231,"interventions":5232},[88],[5211],[5197,5213,5214],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"intervention":5214,"totalTrials":152,"cells":5242},{"EARLY_PHASE1":5243,"PHASE1":5245,"PHASE2":5251,"PHASE3":5253,"PHASE4":5255,"NA":5257},{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[5247],{"nctId":5204,"briefTitle":5205,"status":125,"phases":5248,"primaryCompletion":5207,"completion":5208,"start":5209,"enrollment":321,"conditions":5249,"interventions":5250},[88],[5211],[5197,5213,5214],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"trials":5258,"activeCount":100},[],{"intervention":5260,"totalTrials":152,"cells":5261},"DWJ1558",{"EARLY_PHASE1":5262,"PHASE1":5264,"PHASE2":5276,"PHASE3":5278,"PHASE4":5280,"NA":5282},{"trials":5263,"activeCount":100},[],{"trials":5265,"activeCount":100},[5266],{"nctId":5267,"briefTitle":5268,"status":125,"phases":5269,"primaryCompletion":5270,"completion":5270,"start":5271,"enrollment":5272,"conditions":5273,"interventions":5274},"NCT06010589","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1558 in Healthy Adult Volunteers",[88],"2024-01","2023-08-17",66,[18],[5260,5275],"DWC202310 and DWC202311",{"trials":5277,"activeCount":100},[],{"trials":5279,"activeCount":100},[],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[],{"intervention":5275,"totalTrials":152,"cells":5285},{"EARLY_PHASE1":5286,"PHASE1":5288,"PHASE2":5294,"PHASE3":5296,"PHASE4":5298,"NA":5300},{"trials":5287,"activeCount":100},[],{"trials":5289,"activeCount":100},[5290],{"nctId":5267,"briefTitle":5268,"status":125,"phases":5291,"primaryCompletion":5270,"completion":5270,"start":5271,"enrollment":5272,"conditions":5292,"interventions":5293},[88],[18],[5260,5275],{"trials":5295,"activeCount":100},[],{"trials":5297,"activeCount":100},[],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"intervention":5303,"totalTrials":152,"cells":5304},"Cresto 20mg",{"EARLY_PHASE1":5305,"PHASE1":5307,"PHASE2":5317,"PHASE3":5319,"PHASE4":5321,"NA":5323},{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[5309],{"nctId":5310,"briefTitle":5311,"status":110,"phases":5312,"primaryCompletion":3460,"completion":3460,"start":2135,"enrollment":1685,"conditions":5313,"interventions":5314},"NCT01964365","Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers",[88],[15],[5303,5315,5316],"Fenofibric acid 135mg","Cresto 20mg, Fenofibric acid 135mg",{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[],{"trials":5322,"activeCount":100},[],{"trials":5324,"activeCount":100},[],{"intervention":5315,"totalTrials":152,"cells":5326},{"EARLY_PHASE1":5327,"PHASE1":5329,"PHASE2":5335,"PHASE3":5337,"PHASE4":5339,"NA":5341},{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[5331],{"nctId":5310,"briefTitle":5311,"status":110,"phases":5332,"primaryCompletion":3460,"completion":3460,"start":2135,"enrollment":1685,"conditions":5333,"interventions":5334},[88],[15],[5303,5315,5316],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[],{"trials":5340,"activeCount":100},[],{"trials":5342,"activeCount":100},[],{"intervention":5316,"totalTrials":152,"cells":5344},{"EARLY_PHASE1":5345,"PHASE1":5347,"PHASE2":5353,"PHASE3":5355,"PHASE4":5357,"NA":5359},{"trials":5346,"activeCount":100},[],{"trials":5348,"activeCount":100},[5349],{"nctId":5310,"briefTitle":5311,"status":110,"phases":5350,"primaryCompletion":3460,"completion":3460,"start":2135,"enrollment":1685,"conditions":5351,"interventions":5352},[88],[15],[5303,5315,5316],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"intervention":5362,"totalTrials":152,"cells":5363},"DWJ1451",{"EARLY_PHASE1":5364,"PHASE1":5366,"PHASE2":5376,"PHASE3":5378,"PHASE4":5380,"NA":5382},{"trials":5365,"activeCount":100},[],{"trials":5367,"activeCount":100},[5368],{"nctId":5369,"briefTitle":5370,"status":125,"phases":5371,"primaryCompletion":5372,"completion":5373,"start":5372,"enrollment":4040,"conditions":5374,"interventions":5375},"NCT04819932","Pharmacokinetics and Safety of DWJ1451 in Healthy Adults",[88],"2021-03-13","2021-04-02",[15],[5362],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"intervention":5385,"totalTrials":152,"cells":5386},"Ursodiol",{"EARLY_PHASE1":5387,"PHASE1":5389,"PHASE2":5399,"PHASE3":5401,"PHASE4":5403,"NA":5405},{"trials":5388,"activeCount":100},[],{"trials":5390,"activeCount":100},[5391],{"nctId":5392,"briefTitle":5393,"status":110,"phases":5394,"primaryCompletion":1666,"completion":3313,"start":5395,"enrollment":9,"conditions":5396,"interventions":5397},"NCT02385032","Comparative Bioavailability Study of UDCA",[88],"2015-02",[15],[5385,5398],"URSO Forte",{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[],{"intervention":5398,"totalTrials":152,"cells":5408},{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5417,"PHASE3":5419,"PHASE4":5421,"NA":5423},{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[5413],{"nctId":5392,"briefTitle":5393,"status":110,"phases":5414,"primaryCompletion":1666,"completion":3313,"start":5395,"enrollment":9,"conditions":5415,"interventions":5416},[88],[15],[5385,5398],{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[],{"trials":5424,"activeCount":100},[],{"intervention":5426,"totalTrials":152,"cells":5427},"DWJ1458",{"EARLY_PHASE1":5428,"PHASE1":5430,"PHASE2":5441,"PHASE3":5443,"PHASE4":5445,"NA":5447},{"trials":5429,"activeCount":100},[],{"trials":5431,"activeCount":100},[5432],{"nctId":5433,"briefTitle":5434,"status":4950,"phases":5435,"primaryCompletion":5436,"completion":5437,"start":5438,"enrollment":100,"conditions":5439,"interventions":5440},"NCT04393597","Effects of Food on the Pharmacokinetics of DWJ1458 in Healthy Adults",[88],"2020-07-31","2020-11-30","2020-05-28",[15],[5426,5426],{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[],{"trials":5448,"activeCount":100},[],{"intervention":5450,"totalTrials":152,"cells":5451},"Celecoxib",{"EARLY_PHASE1":5452,"PHASE1":5454,"PHASE2":5467,"PHASE3":5469,"PHASE4":5471,"NA":5473},{"trials":5453,"activeCount":100},[],{"trials":5455,"activeCount":100},[5456],{"nctId":5457,"briefTitle":5458,"status":125,"phases":5459,"primaryCompletion":1238,"completion":5437,"start":5460,"enrollment":5461,"conditions":5462,"interventions":5464},"NCT04490434","Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs",[88],"2020-06-19",110,[5463],"Healthy Male Volunteers",[1803,5450,5465,5466],"Naproxen","Meloxicam",{"trials":5468,"activeCount":100},[],{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"trials":5474,"activeCount":100},[],{"intervention":5465,"totalTrials":152,"cells":5476},{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5485,"PHASE3":5487,"PHASE4":5489,"NA":5491},{"trials":5478,"activeCount":100},[],{"trials":5480,"activeCount":100},[5481],{"nctId":5457,"briefTitle":5458,"status":125,"phases":5482,"primaryCompletion":1238,"completion":5437,"start":5460,"enrollment":5461,"conditions":5483,"interventions":5484},[88],[5463],[1803,5450,5465,5466],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"intervention":5466,"totalTrials":152,"cells":5494},{"EARLY_PHASE1":5495,"PHASE1":5497,"PHASE2":5503,"PHASE3":5505,"PHASE4":5507,"NA":5509},{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[5499],{"nctId":5457,"briefTitle":5458,"status":125,"phases":5500,"primaryCompletion":1238,"completion":5437,"start":5460,"enrollment":5461,"conditions":5501,"interventions":5502},[88],[5463],[1803,5450,5465,5466],{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[],{"intervention":5512,"totalTrials":152,"cells":5513},"Olostar Tab.",{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5526,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[5518],{"nctId":5519,"briefTitle":5520,"status":125,"phases":5521,"primaryCompletion":5522,"completion":5522,"start":5522,"enrollment":1991,"conditions":5523,"interventions":5524},"NCT02561884","A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers",[88],"2015-10",[15],[5512,5525],"Co-administration of Olmetec and Crestor",{"trials":5527,"activeCount":100},[],{"trials":5529,"activeCount":100},[],{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[],{"intervention":5525,"totalTrials":152,"cells":5535},{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5544,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5537,"activeCount":100},[],{"trials":5539,"activeCount":100},[5540],{"nctId":5519,"briefTitle":5520,"status":125,"phases":5541,"primaryCompletion":5522,"completion":5522,"start":5522,"enrollment":1991,"conditions":5542,"interventions":5543},[88],[15],[5512,5525],{"trials":5545,"activeCount":100},[],{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[],{"intervention":5553,"totalTrials":152,"cells":5554},"DWRX2003, 96mg",{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5569,"PHASE3":5571,"PHASE4":5573,"NA":5575},{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[5559],{"nctId":5560,"briefTitle":5561,"status":110,"phases":5562,"primaryCompletion":5563,"completion":5563,"start":5564,"enrollment":321,"conditions":5565,"interventions":5566},"NCT04749173","To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.",[88],"2021-06-18","2020-11-21",[1971],[5553,5567,5568,5568],"DWRX2003, 432mg","DWRX2003, 144mg",{"trials":5570,"activeCount":100},[],{"trials":5572,"activeCount":100},[],{"trials":5574,"activeCount":100},[],{"trials":5576,"activeCount":100},[],{"intervention":5567,"totalTrials":152,"cells":5578},{"EARLY_PHASE1":5579,"PHASE1":5581,"PHASE2":5587,"PHASE3":5589,"PHASE4":5591,"NA":5593},{"trials":5580,"activeCount":100},[],{"trials":5582,"activeCount":100},[5583],{"nctId":5560,"briefTitle":5561,"status":110,"phases":5584,"primaryCompletion":5563,"completion":5563,"start":5564,"enrollment":321,"conditions":5585,"interventions":5586},[88],[1971],[5553,5567,5568,5568],{"trials":5588,"activeCount":100},[],{"trials":5590,"activeCount":100},[],{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[],{"intervention":5568,"totalTrials":152,"cells":5596},{"EARLY_PHASE1":5597,"PHASE1":5599,"PHASE2":5605,"PHASE3":5607,"PHASE4":5609,"NA":5611},{"trials":5598,"activeCount":100},[],{"trials":5600,"activeCount":100},[5601],{"nctId":5560,"briefTitle":5561,"status":110,"phases":5602,"primaryCompletion":5563,"completion":5563,"start":5564,"enrollment":321,"conditions":5603,"interventions":5604},[88],[1971],[5553,5567,5568,5568],{"trials":5606,"activeCount":100},[],{"trials":5608,"activeCount":100},[],{"trials":5610,"activeCount":100},[],{"trials":5612,"activeCount":100},[],{"intervention":5614,"totalTrials":152,"cells":5615},"DWJ1421",{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5630,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[5620],{"nctId":5621,"briefTitle":5622,"status":110,"phases":5623,"primaryCompletion":5624,"completion":5625,"start":5626,"enrollment":277,"conditions":5627,"interventions":5628},"NCT04278391","Pharmacokinetics and Safety Between \"DWJ1421\" and \"DWC201903\" in Healthy Male Volunteers",[88],"2019-08-10","2020-02-19","2019-07-02",[15],[5614,5629],"DWC201903",{"trials":5631,"activeCount":100},[],{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"trials":5637,"activeCount":100},[],{"intervention":5629,"totalTrials":152,"cells":5639},{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5648,"PHASE3":5650,"PHASE4":5652,"NA":5654},{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[5644],{"nctId":5621,"briefTitle":5622,"status":110,"phases":5645,"primaryCompletion":5624,"completion":5625,"start":5626,"enrollment":277,"conditions":5646,"interventions":5647},[88],[15],[5614,5629],{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[],{"intervention":5657,"totalTrials":152,"cells":5658},"Fexuprazan Injection placebo",{"EARLY_PHASE1":5659,"PHASE1":5661,"PHASE2":5674,"PHASE3":5676,"PHASE4":5678,"NA":5680},{"trials":5660,"activeCount":100},[],{"trials":5662,"activeCount":100},[5663],{"nctId":5664,"briefTitle":5665,"status":125,"phases":5666,"primaryCompletion":60,"completion":5667,"start":5668,"enrollment":277,"conditions":5669,"interventions":5670},"NCT06437951","to Evaluate the Safety\u002FTolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection",[88],"2025-05","2024-07",[3497],[5671,5657,5672,5673,5671],"Fexuprazan","Fexuprazan Injection_part 2","Fexuprazan Injection_part 3",{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[],{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[],{"intervention":5672,"totalTrials":152,"cells":5683},{"EARLY_PHASE1":5684,"PHASE1":5686,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5698},{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[5688],{"nctId":5664,"briefTitle":5665,"status":125,"phases":5689,"primaryCompletion":60,"completion":5667,"start":5668,"enrollment":277,"conditions":5690,"interventions":5691},[88],[3497],[5671,5657,5672,5673,5671],{"trials":5693,"activeCount":100},[],{"trials":5695,"activeCount":100},[],{"trials":5697,"activeCount":100},[],{"trials":5699,"activeCount":100},[],{"intervention":5673,"totalTrials":152,"cells":5701},{"EARLY_PHASE1":5702,"PHASE1":5704,"PHASE2":5710,"PHASE3":5712,"PHASE4":5714,"NA":5716},{"trials":5703,"activeCount":100},[],{"trials":5705,"activeCount":100},[5706],{"nctId":5664,"briefTitle":5665,"status":125,"phases":5707,"primaryCompletion":60,"completion":5667,"start":5668,"enrollment":277,"conditions":5708,"interventions":5709},[88],[3497],[5671,5657,5672,5673,5671],{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[],{"trials":5715,"activeCount":100},[],{"trials":5717,"activeCount":100},[],{"intervention":5719,"totalTrials":152,"cells":5720},"Nurigra Chewable",{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5731,"PHASE3":5733,"PHASE4":5735,"NA":5737},{"trials":5722,"activeCount":100},[],{"trials":5724,"activeCount":100},[5725],{"nctId":5726,"briefTitle":5727,"status":110,"phases":5728,"completion":1990,"start":1989,"enrollment":670,"conditions":5729,"interventions":5730},"NCT01651858","Nurigra Chewable Tablet in Healthy Adult Male Volunteers",[88],[15],[5719],{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[],{"trials":5736,"activeCount":100},[],{"trials":5738,"activeCount":100},[],{"intervention":5740,"totalTrials":152,"cells":5741},"Aspirin",{"EARLY_PHASE1":5742,"PHASE1":5744,"PHASE2":5754,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5743,"activeCount":100},[],{"trials":5745,"activeCount":100},[5746],{"nctId":5747,"briefTitle":5748,"status":110,"phases":5749,"primaryCompletion":5750,"completion":5750,"start":5751,"enrollment":321,"conditions":5752,"interventions":5753},"NCT05304845","Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects",[88],"2022-05-22","2022-03-21",[4648],[1803,5740],{"trials":5755,"activeCount":100},[],{"trials":5757,"activeCount":100},[],{"trials":5759,"activeCount":100},[],{"trials":5761,"activeCount":100},[],{"intervention":5763,"totalTrials":152,"cells":5764},"DWJ1567",{"EARLY_PHASE1":5765,"PHASE1":5767,"PHASE2":5777,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5766,"activeCount":100},[],{"trials":5768,"activeCount":100},[5769],{"nctId":5770,"briefTitle":5771,"status":125,"phases":5772,"primaryCompletion":2411,"completion":2411,"start":5773,"enrollment":4312,"conditions":5774,"interventions":5775},"NCT06109259","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1567 in Healthy Adult Volunteers",[88],"2023-11-06",[18],[5763,5776],"DWC202312",{"trials":5778,"activeCount":100},[],{"trials":5780,"activeCount":100},[],{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[],{"intervention":5776,"totalTrials":152,"cells":5786},{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5795,"PHASE3":5797,"PHASE4":5799,"NA":5801},{"trials":5788,"activeCount":100},[],{"trials":5790,"activeCount":100},[5791],{"nctId":5770,"briefTitle":5771,"status":125,"phases":5792,"primaryCompletion":2411,"completion":2411,"start":5773,"enrollment":4312,"conditions":5793,"interventions":5794},[88],[18],[5763,5776],{"trials":5796,"activeCount":100},[],{"trials":5798,"activeCount":100},[],{"trials":5800,"activeCount":100},[],{"trials":5802,"activeCount":100},[],{"intervention":5804,"totalTrials":152,"cells":5805},"Megavec",{"EARLY_PHASE1":5806,"PHASE1":5808,"PHASE2":5817,"PHASE3":5819,"PHASE4":5821,"NA":5823},{"trials":5807,"activeCount":100},[],{"trials":5809,"activeCount":100},[5810],{"nctId":5811,"briefTitle":5812,"status":110,"phases":5813,"primaryCompletion":1990,"completion":1990,"start":1511,"enrollment":277,"conditions":5814,"interventions":5815},"NCT01653314","Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers",[88],[15],[5804,5816],"Glivec",{"trials":5818,"activeCount":100},[],{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[],{"trials":5824,"activeCount":100},[],{"intervention":5816,"totalTrials":152,"cells":5826},{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5835,"PHASE3":5837,"PHASE4":5839,"NA":5841},{"trials":5828,"activeCount":100},[],{"trials":5830,"activeCount":100},[5831],{"nctId":5811,"briefTitle":5812,"status":110,"phases":5832,"primaryCompletion":1990,"completion":1990,"start":1511,"enrollment":277,"conditions":5833,"interventions":5834},[88],[15],[5804,5816],{"trials":5836,"activeCount":100},[],{"trials":5838,"activeCount":100},[],{"trials":5840,"activeCount":100},[],{"trials":5842,"activeCount":100},[],{"intervention":5844,"totalTrials":152,"cells":5845},"DWJ1568",{"EARLY_PHASE1":5846,"PHASE1":5848,"PHASE2":5858,"PHASE3":5860,"PHASE4":5862,"NA":5864},{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[5850],{"nctId":5851,"briefTitle":5852,"status":125,"phases":5853,"primaryCompletion":2411,"completion":2411,"start":5854,"enrollment":4312,"conditions":5855,"interventions":5856},"NCT06119945","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers",[88],"2023-11-09",[18],[5844,5857],"DWC202215",{"trials":5859,"activeCount":100},[],{"trials":5861,"activeCount":100},[],{"trials":5863,"activeCount":100},[],{"trials":5865,"activeCount":100},[],{"intervention":5857,"totalTrials":152,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5876,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[5872],{"nctId":5851,"briefTitle":5852,"status":125,"phases":5873,"primaryCompletion":2411,"completion":2411,"start":5854,"enrollment":4312,"conditions":5874,"interventions":5875},[88],[18],[5844,5857],{"trials":5877,"activeCount":100},[],{"trials":5879,"activeCount":100},[],{"trials":5881,"activeCount":100},[],{"trials":5883,"activeCount":100},[],{"intervention":383,"totalTrials":152,"cells":5885},{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5894,"PHASE3":5896,"PHASE4":5898,"NA":5900},{"trials":5887,"activeCount":100},[],{"trials":5889,"activeCount":100},[5890],{"nctId":376,"briefTitle":377,"status":125,"phases":5891,"primaryCompletion":379,"completion":379,"start":380,"enrollment":321,"conditions":5892,"interventions":5893},[88],[18],[263,383],{"trials":5895,"activeCount":100},[],{"trials":5897,"activeCount":100},[],{"trials":5899,"activeCount":100},[],{"trials":5901,"activeCount":100},[],{"intervention":569,"totalTrials":152,"cells":5903},{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5912,"PHASE3":5914,"PHASE4":5916,"NA":5918},{"trials":5905,"activeCount":100},[],{"trials":5907,"activeCount":100},[5908],{"nctId":561,"briefTitle":562,"status":110,"phases":5909,"primaryCompletion":564,"completion":565,"start":566,"enrollment":321,"conditions":5910,"interventions":5911},[88],[34],[542,569,570],{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[],{"intervention":570,"totalTrials":152,"cells":5921},{"EARLY_PHASE1":5922,"PHASE1":5924,"PHASE2":5930,"PHASE3":5932,"PHASE4":5934,"NA":5936},{"trials":5923,"activeCount":100},[],{"trials":5925,"activeCount":100},[5926],{"nctId":561,"briefTitle":562,"status":110,"phases":5927,"primaryCompletion":564,"completion":565,"start":566,"enrollment":321,"conditions":5928,"interventions":5929},[88],[34],[542,569,570],{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[],{"trials":5935,"activeCount":100},[],{"trials":5937,"activeCount":100},[],{"intervention":5939,"totalTrials":152,"cells":5940},"DWC202005, alone",{"EARLY_PHASE1":5941,"PHASE1":5943,"PHASE2":5954,"PHASE3":5956,"PHASE4":5958,"NA":5960},{"trials":5942,"activeCount":100},[],{"trials":5944,"activeCount":100},[5945],{"nctId":5946,"briefTitle":5947,"status":110,"phases":5948,"primaryCompletion":5564,"completion":5564,"start":5949,"enrollment":604,"conditions":5950,"interventions":5951},"NCT04328766","Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers",[88],"2020-09-06",[5211],[5939,5952,5953],"DWP14012 + DWC202005","DWP14012 + DWC202005, after multiple doses of DWP14012",{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[],{"trials":5961,"activeCount":100},[],{"intervention":5952,"totalTrials":152,"cells":5963},{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5972,"PHASE3":5974,"PHASE4":5976,"NA":5978},{"trials":5965,"activeCount":100},[],{"trials":5967,"activeCount":100},[5968],{"nctId":5946,"briefTitle":5947,"status":110,"phases":5969,"primaryCompletion":5564,"completion":5564,"start":5949,"enrollment":604,"conditions":5970,"interventions":5971},[88],[5211],[5939,5952,5953],{"trials":5973,"activeCount":100},[],{"trials":5975,"activeCount":100},[],{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[],{"intervention":5953,"totalTrials":152,"cells":5981},{"EARLY_PHASE1":5982,"PHASE1":5984,"PHASE2":5990,"PHASE3":5992,"PHASE4":5994,"NA":5996},{"trials":5983,"activeCount":100},[],{"trials":5985,"activeCount":100},[5986],{"nctId":5946,"briefTitle":5947,"status":110,"phases":5987,"primaryCompletion":5564,"completion":5564,"start":5949,"enrollment":604,"conditions":5988,"interventions":5989},[88],[5211],[5939,5952,5953],{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[],{"trials":5997,"activeCount":100},[],{"intervention":3712,"totalTrials":152,"cells":5999},{"EARLY_PHASE1":6000,"PHASE1":6002,"PHASE2":6008,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":6001,"activeCount":100},[],{"trials":6003,"activeCount":100},[6004],{"nctId":3704,"briefTitle":3705,"status":125,"phases":6005,"primaryCompletion":3707,"completion":3708,"start":3709,"enrollment":670,"conditions":6006,"interventions":6007},[88],[15],[3687,3712],{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"intervention":4008,"totalTrials":152,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6026,"PHASE3":6028,"PHASE4":6030,"NA":6032},{"trials":6019,"activeCount":100},[],{"trials":6021,"activeCount":100},[6022],{"nctId":4000,"briefTitle":4001,"status":110,"phases":6023,"primaryCompletion":4003,"completion":4004,"start":4005,"enrollment":670,"conditions":6024,"interventions":6025},[88],[15],[3984,4008],{"trials":6027,"activeCount":100},[],{"trials":6029,"activeCount":100},[],{"trials":6031,"activeCount":100},[],{"trials":6033,"activeCount":100},[],{"intervention":3721,"totalTrials":152,"cells":6035},{"EARLY_PHASE1":6036,"PHASE1":6038,"PHASE2":6044,"PHASE3":6046,"PHASE4":6048,"NA":6050},{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[6040],{"nctId":3714,"briefTitle":3715,"status":110,"phases":6041,"primaryCompletion":1709,"completion":3717,"start":3718,"enrollment":1426,"conditions":6042,"interventions":6043},[88],[15],[3687,3721],{"trials":6045,"activeCount":100},[],{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[],{"trials":6051,"activeCount":100},[],{"intervention":4043,"totalTrials":152,"cells":6053},{"EARLY_PHASE1":6054,"PHASE1":6056,"PHASE2":6062,"PHASE3":6064,"PHASE4":6066,"NA":6068},{"trials":6055,"activeCount":100},[],{"trials":6057,"activeCount":100},[6058],{"nctId":4034,"briefTitle":4035,"status":110,"phases":6059,"primaryCompletion":4037,"completion":4038,"start":4039,"enrollment":4040,"conditions":6060,"interventions":6061},[88],[15],[4018,4043],{"trials":6063,"activeCount":100},[],{"trials":6065,"activeCount":100},[],{"trials":6067,"activeCount":100},[],{"trials":6069,"activeCount":100},[],{"intervention":6071,"totalTrials":152,"cells":6072},"Erdos",{"EARLY_PHASE1":6073,"PHASE1":6075,"PHASE2":6087,"PHASE3":6089,"PHASE4":6091,"NA":6093},{"trials":6074,"activeCount":100},[],{"trials":6076,"activeCount":100},[6077],{"nctId":6078,"briefTitle":6079,"status":110,"phases":6080,"primaryCompletion":6081,"completion":4791,"start":6082,"enrollment":604,"conditions":6083,"interventions":6084},"NCT02332044","Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers",[88],"2014-09","2014-04",[15],[6071,6085,6086],"Talion","Erdos, Talion",{"trials":6088,"activeCount":100},[],{"trials":6090,"activeCount":100},[],{"trials":6092,"activeCount":100},[],{"trials":6094,"activeCount":100},[],{"intervention":6085,"totalTrials":152,"cells":6096},{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6105,"PHASE3":6107,"PHASE4":6109,"NA":6111},{"trials":6098,"activeCount":100},[],{"trials":6100,"activeCount":100},[6101],{"nctId":6078,"briefTitle":6079,"status":110,"phases":6102,"primaryCompletion":6081,"completion":4791,"start":6082,"enrollment":604,"conditions":6103,"interventions":6104},[88],[15],[6071,6085,6086],{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[],{"trials":6110,"activeCount":100},[],{"trials":6112,"activeCount":100},[],{"intervention":6086,"totalTrials":152,"cells":6114},{"EARLY_PHASE1":6115,"PHASE1":6117,"PHASE2":6123,"PHASE3":6125,"PHASE4":6127,"NA":6129},{"trials":6116,"activeCount":100},[],{"trials":6118,"activeCount":100},[6119],{"nctId":6078,"briefTitle":6079,"status":110,"phases":6120,"primaryCompletion":6081,"completion":4791,"start":6082,"enrollment":604,"conditions":6121,"interventions":6122},[88],[15],[6071,6085,6086],{"trials":6124,"activeCount":100},[],{"trials":6126,"activeCount":100},[],{"trials":6128,"activeCount":100},[],{"trials":6130,"activeCount":100},[],{"intervention":6132,"totalTrials":152,"cells":6133},"DWC20151",{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6145,"PHASE3":6147,"PHASE4":6149,"NA":6151},{"trials":6135,"activeCount":100},[],{"trials":6137,"activeCount":100},[6138],{"nctId":6139,"briefTitle":6140,"status":110,"phases":6141,"primaryCompletion":1282,"completion":3106,"start":4790,"enrollment":1991,"conditions":6142,"interventions":6143},"NCT02502721","A Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152",[88],[15],[6132,6144],"DWC20152",{"trials":6146,"activeCount":100},[],{"trials":6148,"activeCount":100},[],{"trials":6150,"activeCount":100},[],{"trials":6152,"activeCount":100},[],{"intervention":6144,"totalTrials":152,"cells":6154},{"EARLY_PHASE1":6155,"PHASE1":6157,"PHASE2":6163,"PHASE3":6165,"PHASE4":6167,"NA":6169},{"trials":6156,"activeCount":100},[],{"trials":6158,"activeCount":100},[6159],{"nctId":6139,"briefTitle":6140,"status":110,"phases":6160,"primaryCompletion":1282,"completion":3106,"start":4790,"enrollment":1991,"conditions":6161,"interventions":6162},[88],[15],[6132,6144],{"trials":6164,"activeCount":100},[],{"trials":6166,"activeCount":100},[],{"trials":6168,"activeCount":100},[],{"trials":6170,"activeCount":100},[],{"intervention":393,"totalTrials":152,"cells":6172},{"EARLY_PHASE1":6173,"PHASE1":6175,"PHASE2":6181,"PHASE3":6183,"PHASE4":6185,"NA":6187},{"trials":6174,"activeCount":100},[],{"trials":6176,"activeCount":100},[6177],{"nctId":385,"briefTitle":386,"status":125,"phases":6178,"primaryCompletion":388,"completion":389,"start":390,"enrollment":16,"conditions":6179,"interventions":6180},[88],[15],[263,393,394],{"trials":6182,"activeCount":100},[],{"trials":6184,"activeCount":100},[],{"trials":6186,"activeCount":100},[],{"trials":6188,"activeCount":100},[],{"intervention":394,"totalTrials":152,"cells":6190},{"EARLY_PHASE1":6191,"PHASE1":6193,"PHASE2":6199,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6192,"activeCount":100},[],{"trials":6194,"activeCount":100},[6195],{"nctId":385,"briefTitle":386,"status":125,"phases":6196,"primaryCompletion":388,"completion":389,"start":390,"enrollment":16,"conditions":6197,"interventions":6198},[88],[15],[263,393,394],{"trials":6200,"activeCount":100},[],{"trials":6202,"activeCount":100},[],{"trials":6204,"activeCount":100},[],{"trials":6206,"activeCount":100},[],{"intervention":1244,"totalTrials":152,"cells":6208},{"EARLY_PHASE1":6209,"PHASE1":6211,"PHASE2":6217,"PHASE3":6219,"PHASE4":6221,"NA":6223},{"trials":6210,"activeCount":100},[],{"trials":6212,"activeCount":100},[6213],{"nctId":1235,"briefTitle":1236,"status":125,"phases":6214,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":6215,"interventions":6216},[88],[15],[1244,1228,1245,1246],{"trials":6218,"activeCount":100},[],{"trials":6220,"activeCount":100},[],{"trials":6222,"activeCount":100},[],{"trials":6224,"activeCount":100},[],{"intervention":1245,"totalTrials":152,"cells":6226},{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6235,"PHASE3":6237,"PHASE4":6239,"NA":6241},{"trials":6228,"activeCount":100},[],{"trials":6230,"activeCount":100},[6231],{"nctId":1235,"briefTitle":1236,"status":125,"phases":6232,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":6233,"interventions":6234},[88],[15],[1244,1228,1245,1246],{"trials":6236,"activeCount":100},[],{"trials":6238,"activeCount":100},[],{"trials":6240,"activeCount":100},[],{"trials":6242,"activeCount":100},[],{"intervention":1246,"totalTrials":152,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6253,"PHASE3":6255,"PHASE4":6257,"NA":6259},{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[6249],{"nctId":1235,"briefTitle":1236,"status":125,"phases":6250,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":6251,"interventions":6252},[88],[15],[1244,1228,1245,1246],{"trials":6254,"activeCount":100},[],{"trials":6256,"activeCount":100},[],{"trials":6258,"activeCount":100},[],{"trials":6260,"activeCount":100},[],{"intervention":1803,"totalTrials":6262,"cells":6263},11,{"EARLY_PHASE1":6264,"PHASE1":6266,"PHASE2":6311,"PHASE3":6317,"PHASE4":6329,"NA":6331},{"trials":6265,"activeCount":100},[],{"trials":6267,"activeCount":100},[6268,6272,6276,6280,6290,6294,6298,6307],{"nctId":4685,"briefTitle":4686,"status":125,"phases":6269,"primaryCompletion":4688,"completion":4689,"start":4690,"enrollment":604,"conditions":6270,"interventions":6271},[88],[4648],[1803,4678],{"nctId":4745,"briefTitle":4746,"status":110,"phases":6273,"primaryCompletion":4748,"completion":4748,"start":4749,"enrollment":604,"conditions":6274,"interventions":6275},[88],[4648],[1803,4738,4752],{"nctId":1795,"briefTitle":1796,"status":125,"phases":6277,"primaryCompletion":566,"completion":1798,"start":1799,"enrollment":604,"conditions":6278,"interventions":6279},[88],[15],[1772,1802,1803],{"nctId":6281,"briefTitle":6282,"status":110,"phases":6283,"primaryCompletion":6284,"completion":6285,"start":6286,"enrollment":6287,"conditions":6288,"interventions":6289},"NCT06508645","Study to Evaluate the Safety\u002FTolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers",[88],"2022-03-29","2022-04-06","2022-01-10",33,[18],[1803],{"nctId":5457,"briefTitle":5458,"status":125,"phases":6291,"primaryCompletion":1238,"completion":5437,"start":5460,"enrollment":5461,"conditions":6292,"interventions":6293},[88],[5463],[1803,5450,5465,5466],{"nctId":5747,"briefTitle":5748,"status":110,"phases":6295,"primaryCompletion":5750,"completion":5750,"start":5751,"enrollment":321,"conditions":6296,"interventions":6297},[88],[4648],[1803,5740],{"nctId":6299,"briefTitle":6300,"status":110,"phases":6301,"primaryCompletion":6302,"completion":6303,"start":6304,"enrollment":1513,"conditions":6305,"interventions":6306},"NCT03574415","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean",[88],"2019-01-18","2019-01-23","2018-11-01",[18],[1803],{"nctId":3479,"briefTitle":3480,"status":110,"phases":6308,"primaryCompletion":3482,"completion":3482,"start":3483,"enrollment":3484,"conditions":6309,"interventions":6310},[88],[15],[1803,3472],{"trials":6312,"activeCount":100},[6313],{"nctId":3490,"briefTitle":3491,"status":110,"phases":6314,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":3495,"conditions":6315,"interventions":6316},[89],[3497],[1803,3472,3499,3500],{"trials":6318,"activeCount":100},[6319],{"nctId":6320,"briefTitle":6321,"status":110,"phases":6322,"primaryCompletion":6323,"completion":6324,"start":128,"enrollment":6325,"conditions":6326,"interventions":6328},"NCT05813561","The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis",[90],"2022-07-23","2023-02-17",332,[6327],"Reflux Esophagitis",[1803],{"trials":6330,"activeCount":100},[],{"trials":6332,"activeCount":100},[6333],{"nctId":6334,"briefTitle":6335,"status":125,"phases":6336,"primaryCompletion":6337,"completion":128,"start":6338,"enrollment":6339,"conditions":6340,"interventions":6341},"NCT04613895","Treatment Effect According to Timing of Administration of DWP14012 40 mg",[92],"2021-05-30","2020-11-17",186,[1838],[1803,1803],{"intervention":5671,"totalTrials":615,"cells":6343},{"EARLY_PHASE1":6344,"PHASE1":6346,"PHASE2":6352,"PHASE3":6354,"PHASE4":6356,"NA":6358},{"trials":6345,"activeCount":100},[],{"trials":6347,"activeCount":100},[6348],{"nctId":5664,"briefTitle":5665,"status":125,"phases":6349,"primaryCompletion":60,"completion":5667,"start":5668,"enrollment":277,"conditions":6350,"interventions":6351},[88],[3497],[5671,5657,5672,5673,5671],{"trials":6353,"activeCount":100},[],{"trials":6355,"activeCount":100},[],{"trials":6357,"activeCount":100},[],{"trials":6359,"activeCount":100},[6360],{"nctId":6361,"briefTitle":6362,"status":110,"phases":6363,"primaryCompletion":40,"completion":6364,"start":6365,"enrollment":6366,"conditions":6367,"interventions":6369},"NCT05614752","Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab",[],"2024-11-08","2022-07-06",10067,[6368],"Gastroesophageal Reflux Disease",[5671],{"intervention":6371,"totalTrials":615,"cells":6372},"Fexuprazan Hydrochloride",{"EARLY_PHASE1":6373,"PHASE1":6375,"PHASE2":6377,"PHASE3":6379,"PHASE4":6381,"NA":6383},{"trials":6374,"activeCount":100},[],{"trials":6376,"activeCount":100},[],{"trials":6378,"activeCount":100},[],{"trials":6380,"activeCount":100},[],{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[6385,6393],{"nctId":6386,"briefTitle":6387,"status":110,"phases":6388,"primaryCompletion":360,"completion":55,"start":6389,"enrollment":6390,"conditions":6391,"interventions":6392},"NCT05886933","Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet",[],"2023-05-22",9846,[6368],[6371],{"nctId":6394,"briefTitle":6395,"status":110,"phases":6396,"primaryCompletion":6397,"completion":6398,"start":6399,"enrollment":6400,"conditions":6401,"interventions":6402},"NCT05660122","A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab",[],"2024-12-26","2025-08-11","2022-11-11",2852,[6368],[6371],{"intervention":6404,"totalTrials":615,"cells":6405},"Other: Not applicable-observational study",{"EARLY_PHASE1":6406,"PHASE1":6408,"PHASE2":6410,"PHASE3":6412,"PHASE4":6414,"NA":6416},{"trials":6407,"activeCount":100},[],{"trials":6409,"activeCount":100},[],{"trials":6411,"activeCount":100},[],{"trials":6413,"activeCount":100},[],{"trials":6415,"activeCount":100},[],{"trials":6417,"activeCount":100},[6418,6427],{"nctId":6419,"briefTitle":6420,"status":125,"phases":6421,"primaryCompletion":6422,"start":1424,"enrollment":6423,"conditions":6424,"interventions":6426},"NCT02946450","Observational Study to Assess the Safety of Omnipure® Inj.(Iohexol) Contrast Media in CT Scanning Patients",[],"2016-12",3000,[6425],"CT Scanning Patients",[6404],{"nctId":6428,"briefTitle":6429,"status":125,"phases":6430,"primaryCompletion":6431,"completion":6431,"start":2300,"enrollment":6432,"conditions":6433,"interventions":6434},"NCT03009721","Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia",[],"2018-06",9707,[20,26],[6404],{"intervention":6436,"totalTrials":152,"cells":6437},"Litorvazet Tablet 10\u002F10mg",{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6444,"PHASE4":6446,"NA":6448},{"trials":6439,"activeCount":100},[],{"trials":6441,"activeCount":100},[],{"trials":6443,"activeCount":100},[],{"trials":6445,"activeCount":100},[],{"trials":6447,"activeCount":100},[],{"trials":6449,"activeCount":100},[6450],{"nctId":6451,"briefTitle":6452,"status":110,"phases":6453,"primaryCompletion":40,"completion":6454,"start":6455,"enrollment":6423,"conditions":6456,"interventions":6457},"NCT06866509","To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients",[],"2024-02-28","2022-02-28",[32],[6436,6458,6459],"Litorvazet Tablet10\u002F20mg","Litorvazet Tablet 10\u002F40mg",{"intervention":6458,"totalTrials":152,"cells":6461},{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6472},{"trials":6463,"activeCount":100},[],{"trials":6465,"activeCount":100},[],{"trials":6467,"activeCount":100},[],{"trials":6469,"activeCount":100},[],{"trials":6471,"activeCount":100},[],{"trials":6473,"activeCount":100},[6474],{"nctId":6451,"briefTitle":6452,"status":110,"phases":6475,"primaryCompletion":40,"completion":6454,"start":6455,"enrollment":6423,"conditions":6476,"interventions":6477},[],[32],[6436,6458,6459],{"intervention":6459,"totalTrials":152,"cells":6479},{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6490},{"trials":6481,"activeCount":100},[],{"trials":6483,"activeCount":100},[],{"trials":6485,"activeCount":100},[],{"trials":6487,"activeCount":100},[],{"trials":6489,"activeCount":100},[],{"trials":6491,"activeCount":100},[6492],{"nctId":6451,"briefTitle":6452,"status":110,"phases":6493,"primaryCompletion":40,"completion":6454,"start":6455,"enrollment":6423,"conditions":6494,"interventions":6495},[],[32],[6436,6458,6459],{"intervention":6497,"totalTrials":152,"cells":6498},"Olmesartan Medoxomil",{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6505,"PHASE4":6507,"NA":6509},{"trials":6500,"activeCount":100},[],{"trials":6502,"activeCount":100},[],{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":100},[],{"trials":6508,"activeCount":100},[],{"trials":6510,"activeCount":100},[6511],{"nctId":6512,"briefTitle":6513,"status":110,"phases":6514,"primaryCompletion":3831,"completion":3831,"start":6515,"enrollment":6516,"conditions":6517,"interventions":6518},"NCT05184179","Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab",[],"2019-12-01",5450,[20,32],[6497],{"intervention":6520,"totalTrials":152,"cells":6521},"Clopidogrel",{"EARLY_PHASE1":6522,"PHASE1":6524,"PHASE2":6526,"PHASE3":6528,"PHASE4":6530,"NA":6532},{"trials":6523,"activeCount":100},[],{"trials":6525,"activeCount":100},[],{"trials":6527,"activeCount":100},[],{"trials":6529,"activeCount":100},[],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[6534],{"nctId":6535,"briefTitle":6536,"status":125,"phases":6537,"primaryCompletion":1357,"completion":1357,"start":2028,"enrollment":6538,"conditions":6539,"interventions":6541},"NCT02953405","Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease",[],1000,[6540],"MCA - Middle Cerebral Artery Dissection",[6520],{"intervention":6543,"totalTrials":152,"cells":6544},"Sarpogrelate",{"EARLY_PHASE1":6545,"PHASE1":6547,"PHASE2":6549,"PHASE3":6551,"PHASE4":6553,"NA":6555},{"trials":6546,"activeCount":100},[],{"trials":6548,"activeCount":100},[],{"trials":6550,"activeCount":100},[],{"trials":6552,"activeCount":100},[],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[6557],{"nctId":6558,"briefTitle":6559,"status":110,"phases":6560,"primaryCompletion":6561,"completion":6561,"start":6562,"enrollment":6563,"conditions":6564,"interventions":6566},"NCT05083299","Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate",[],"2022-01-20","2020-01-28",1003,[6565],"Chronic Occlusive Arterial Disease",[6543]]